[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 469
1. Garcia JJ, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Reuter VE, Fine SW: Do prostatic transition zone tumors have a distinct morphology? Am J Surg Pathol; 2008 Nov;32(11):1709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do prostatic transition zone tumors have a distinct morphology?
  • Previous studies have proposed that the morphologic spectrum of prostatic glands of variable size with tall columnar cells displaying basally oriented nuclei and clear to pale pink cytoplasm (TZ-LOOK) is characteristic of the well to moderately differentiated component of transition zone (TZ) tumors.
  • In a recent report, we identified dominant peripheral zone (PZ) and TZ tumors situated anterior to the prostatic urethra.
  • Currently, we evaluate the histopathologic features of 215 dominant tumors, including 63 TZ and 73 anterior PZ lesions and an additional cohort of 79 posterior PZ tumors, in radical prostatectomy specimens, to identify the prevalence of this morphology in tumors of different zonal origin.
  • Each dominant tumor was assigned a TZ-LOOK extent score of 0 to 4, with 0 = no such morphology, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = >75%.
  • Overall, 121/215 (56%) tumors showed some degree of this histology, including 56 of 63 (89%) TZ tumors and 65 of 152 (43%) PZ tumors (P<0.0001).
  • However, only 31/63 (49%) TZ tumors had >50% TZ-LOOK.
  • Among PZ tumors, 6/152 (4%) had predominant (>50%) TZ-LOOK morphology, yet 23/152 (15%) of all PZ tumors and 23/65 (35%) of PZ tumors displaying any degree of TZ-LOOK had scores of 2 to 3 (>25%; nonfocal).
  • In tumors of both zones with predominant (scores 3 to 4; >50%) TZ-LOOK histology, darker glands of usual acinar adenocarcinoma was often seen at the periphery.
  • Conversely, in tumors with nonpredominant TZ-LOOK (scores 1 to 2; <or=50%), these glands were frequently admixed with small glands bearing dark cytoplasm.
  • In this series, we demonstrate that some degree of TZ-LOOK morphology is twice as frequent in dominant TZ tumors than in PZ tumors.
  • Tumors demonstrating >50% of this histology are very likely of TZ origin, but this scenario occurs in only half of TZ tumors.
  • Importantly, the TZ-LOOK is nonfocal in up to 35% of PZ tumors exhibiting any degree of this morphology.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:267-9 [7823599.001]
  • [Cites] Urology. 2003 Apr;61(4):748-53 [12670559.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]
  • [Cites] J Urol. 1995 Nov;154(5):1795-7 [7563349.001]
  • [Cites] J Urol. 1996 Feb;155(2):605-6 [8558670.001]
  • [Cites] Urology. 1996 Nov;48(5):751-6 [8911519.001]
  • [Cites] J Urol. 1997 Jan;157(1):204-6 [8976251.001]
  • [Cites] J Urol. 1997 Feb;157(2):556-8 [8996355.001]
  • [Cites] J Urol. 1997 Nov;158(5):1886-90 [9334623.001]
  • [Cites] Int J Urol. 1997 Nov;4(6):567-71 [9477185.001]
  • [Cites] Urology. 1998 Jul;52(1):89-93 [9671876.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1239-46 [9777986.001]
  • [Cites] Eur Urol. 1999 Apr;35(4):294-7 [10087391.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1221-5 [15610093.001]
  • [Cites] J Urol. 2005 Mar;173(3):737-41 [15711259.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1189-93 [14501722.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Pathology. 2003 Dec;35(6):467-71 [14660095.001]
  • [Cites] Invest Urol. 1978 Jan;15(4):340-5 [75197.001]
  • [Cites] Prostate. 1981;2(1):35-49 [7279811.001]
  • [Cites] J Urol. 1988 Jan;139(1):61-5 [3336108.001]
  • [Cites] Am J Surg Pathol. 1988 Aug;12(8):619-33 [2456702.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):897-906 [3202246.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] J Urol. 1991 Jul;146(1):78-83; discussion 83-4 [1711589.001]
  • [Cites] J Urol. 1991 Oct;146(4):1069-76 [1895423.001]
  • [Cites] Br J Urol. 1991 Nov;68(5):499-509 [1747726.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):258-66 [1555836.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] Cancer Invest. 1994;12(4):425-37 [8032966.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]
  • [Cites] Urol Int. 2005;74(1):23-6 [15711104.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):916-21; discussion 921 [16126324.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1167-71 [17026586.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):430-5 [17412489.001]
  • [Cites] Adv Anat Pathol. 2007 Nov;14(6):401-7 [18049129.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):229-35 [18223325.001]
  • [Cites] J Urol. 2008 Apr;179(4):1335-8; discussion 1338-9 [18289601.001]
  • [Cites] J Urol. 2000 Jun;163(6):1751-5 [10799175.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1039-46 [10935644.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):441-6 [11331962.001]
  • [Cites] BJU Int. 2002 Jan;89(1):33-9 [11849157.001]
  • [Cites] Urology. 2001 Jun;57(6):1117-20 [11377321.001]
  • [Cites] BJU Int. 2002 Jun;89(9):886-9 [12010233.001]
  • [Cites] Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22 [7754280.001]
  • (PMID = 18769336.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092629-10; United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / P50 CA092629-10
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS237591; NLM/ PMC3010973
  •  go-up   go-down


2. Pan Z, Erkan M, Streit S, Friess H, Kleeff J: Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. Int J Oncol; 2009 Oct;35(4):823-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we investigated the expression and the role of GRP94 in regulating cell growth and apoptosis in pancreatic cancer cells.
  • Immunohistochemistry was performed to localize GRP94 in tissues of the normal pancreas (n=20), chronic pancreatitis (n=20) and pancreatic ductal adenocarcinoma (n=44).
  • GRP94 protein was strongly expressed in normal acinar cells and moderately expressed in normal ductal cells.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Glycoproteins / metabolism. Pancreatic Neoplasms / metabolism. RNA Interference. RNA, Small Interfering / metabolism
  • [MeSH-minor] Cell Line, Tumor. Dactinomycin / pharmacology. Dose-Response Relationship, Drug. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Nucleic Acid Synthesis Inhibitors / pharmacology. Prognosis. Protein Synthesis Inhibitors / pharmacology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724918.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / endoplasmin; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


3. Liu YL, Matsuzaki T, Nakazawa T, Murata S, Nakamura N, Kondo T, Iwashina M, Mochizuki K, Yamane T, Takata K, Katoh R: Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. Hum Pathol; 2007 Jan;38(1):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the expression of AQP3 in normal and neoplastic lung tissues, we studied a series of 149 lung carcinoma tissues and 2 cell lines by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction.
  • In lung carcinomas, AQP3 expression was observed in 59 (70.2%) of 84 adenocarcinomas.
  • Squamous cell carcinoma and large cell carcinoma had rather low positive ratios (35.8% and 13.4%, respectively).
  • No AQP3 expression was demonstrated in small cell carcinoma, pleomorphic carcinoma, or metastatic colon adenocarcinoma.
  • In adenocarcinomas, AQP3 was detected in all tumors of bronchioloalveolar subtype.
  • Papillary subtype also showed a higher positive ratio of AQP3 compared with that in acinar and solid with mucin subtypes.
  • In addition, AQP3 expression was related to tumor differentiation and clinical stage in adenocarcinomas.
  • Western blotting and reverse transcriptase-polymerase chain reaction analyses confirmed the expression of AQP3 protein and messenger RNA in cell lines and tissues of lung adenocarcinoma.
  • In addition, lung carcinomas, especially adenocarcinomas, can produce AQP3, possibly in connection with their functional and/or biological nature, although the detailed mechanism of AQP3 expression in lung carcinomas remains to be clarified.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056099.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3
  •  go-up   go-down


Advertisement
4. Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW, Rudrick BF: Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J; 2008 Oct;2(5):518-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rates of diagnosis from prostate gland biopsies of benign (17.6%), high-grade prostatic intraepithelial neoplasia (11.0%), atypical small acinar proliferation suspicious for invasive malignancy (13.2%) and invasive prostatic adenocarcinoma (58.2%) at our institution were significantly different than those reported in the literature (p < 0.001).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2007 Mar;177(3):903-6 [17296372.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1818-23 [11042578.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Histopathology. 2006 May;48(6):655-62 [16681680.001]
  • [Cites] Histopathology. 2006 May;48(6):644-54 [16681679.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1004-10 [16048389.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):228-34 [15475927.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):687-92 [10420224.001]
  • [Cites] Urology. 1998 Feb;51(2):186-95 [9495696.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1007-8 [12873176.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):81-8 [11172299.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] J Urol. 2006 Sep;176(3):979-84; discussion 984 [16890675.001]
  • (PMID = 18953449.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2572237
  •  go-up   go-down


5. Lomberk G: Funding opportunities for rare pancreatic diseases. Pancreatology; 2009;9(4):327-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additional rare diseases which remain 'funding orphans' include certain cancers such as acinar carcinoma, autoimmune pancreatitis, and various types of diseases characterized by cysts, both benign and malignant, among others.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19468246.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Skálová A, Sima R, Vanecek T, Muller S, Korabecna M, Nemcova J, Elmberger G, Leivo I, Passador-Santos F, Walter J, Rousarova M, Jedlickova K, Curik R, Geierova M, Michal M: Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol; 2009 Aug;33(8):1137-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes.
  • High-grade transformation of acinic cell carcinoma (AciCC) (previously referred to as dedifferentiation) is a rare phenomenon characterized by histologic progression of low-grade AciCC to high-grade adenocarcinoma or undifferentiated carcinoma.
  • We report 9 new cases with immunohistochemical analysis and examination of HER-2/neu and p53 genes to further define the profile of this tumor.
  • Six of 9 patients (66%) died from tumor dissemination, all with a median overall survival of 4.3 years (range: 1 to 9 y).
  • The high propensity for LN metastases indicates the need for neck dissection at the time of diagnosis.
  • [MeSH-major] Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / pathology. Genes, erbB-2. Genes, p53. Parotid Neoplasms / genetics. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


7. Yu DC, Kozakewich HP, Perez-Atayde AR, Shamberger RC, Weldon CB: Childhood pancreatic tumors: a single institution experience. J Pediatr Surg; 2009 Dec;44(12):2267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood pancreatic tumors: a single institution experience.
  • The most common were gastroenteropancreatic neuroendocrine, solid pseudopapillary, and acinar tumors.
  • There were 6 benign and 12 malignant tumors.
  • Six patients had disease outside the pancreas at their initial operation.
  • There were 7 deaths (41%), 2 related to the initial operation, 3 from disease progression, 1 from a small bowel obstruction, and 1 from necrotizing pancreatitis.
  • Five deaths were in patients with extrapancreatic disease found at initial operation.
  • CONCLUSION: In adults, pancreatic ductal adenocarcinoma is by far the most common histopathologic subtype, with other subtypes more common in children.
  • Long-term disease-free survival in childhood pancreatic malignancies is achievable with complete surgical resection, prognosis, and adjuvant treatment, depending on the histopathologic type.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Child. Child, Preschool. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Neoplasm Staging. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Prognosis. Retrospective Studies. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006007.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Cheng L, MacLennan GT, Abdul-Karim FW, Lopez-Beltran A, Montironi R: Eosinophilic metaplasia of the prostate: a newly described lesion distinct from other eosinophilic changes in prostatic epithelium. Anal Quant Cytol Histol; 2008 Aug;30(4):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the morphologic, immunohistochemical and ultrastructural features of large, intensely eosinophilic cytoplasmic granules in prostatic epithelial cells in the benign prostate, as well as the prevalence of this condition.
  • RESULTS: We found benign prostatic cells with bright eosinophilic granules in 13 of 84 (16%) negative prostate needle biopsies, 3 of 13 (23%) needle biopsies with high-grade prostatic intraepithelial neoplasia, 15 of 123 (12%) needle biopsies with adenocarcinoma and 21 of 104 (20%) radical prostatectomy specimens.
  • Benign prostatic cells with eosinophilic granules were more commonly seen in prostatic ductal epithelium than acinar epithelium.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773741.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Mocan S, Stolnicu S, Rădulescu D, Petrovan C: [Acinic cell adenocarcinoma of the lip]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell adenocarcinoma of the lip].
  • [Transliterated title] Adenocarcinom cu celule acinare cu localizare la nivelul buzei. Prezentare de caz.
  • The variable histological appearance of acinic cell carcinoma coupled with its uncommon occurrence account for considerable diagnostic difficulties.
  • Different cellular features were recognised in the tumour, with the presence of both serous and mucous acinar differentiation.
  • Acinic cell adenocarcinoma is a malignant epithelial neoplasm in which the neoplastic cells demonstrate not only serous acinar differentiation.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Lip Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607848.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


10. Logsdon CD, Ji B: Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol; 2009 Nov;7(11 Suppl):S40-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer.
  • The relationship between chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) is unclear.
  • However, we have recently found that excessive activity within the Ras signaling pathway can lead to acinar cell death or metaplasia and is associated with the development of fibrosis resembling CP and the development of PDAC from acinar cells through the full complement of preneoplastic (pancreatic intraepithelial neoplasia) lesions.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):31-7 [10228761.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):242-6 [9324130.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):81-91 [15731576.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101 [16169155.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2165-78 [16762637.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Adv Med Sci. 2006;51:23-30 [17357272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1557-73 [17466744.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] Neoplasia. 2008 Aug;10(8):782-96 [18670639.001]
  • [Cites] Biochem Biophys Res Commun. 2009 May 8;382(3):561-5 [19292977.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Int J Pancreatol. 2000 Apr;27(2):93-103 [10862508.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):286-93 [11159909.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Pancreas. 2003 Nov;27(4):297-300 [14576490.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] World J Gastroenterol. 2004 Mar 15;10(6):881-4 [15040037.001]
  • [Cites] Endoscopy. 2004 Jun;36(6):535-42 [15202051.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982 Aug;396(3):331-49 [7135827.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Acta Cytol. 1989 Nov-Dec;33(6):870-4 [2588919.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1700-4 [8213710.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):625-7 [8145277.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2761-4 [8168108.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] N Engl J Med. 1995 Jun 1;332(22):1482-90 [7739686.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):247-51 [7797022.001]
  • [Cites] Ann Intern Med. 1995 Aug 1;123(3):188-91 [7598300.001]
  • [Cites] Am J Physiol. 1995 Jun;268(6 Pt 1):G1060-5 [7611406.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4264-7 [7671233.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Neoplasma. 2004;51(5):400-4 [15640947.001]
  • (PMID = 19896097.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK052067-11; United States / NCI NIH HHS / CA / P30 CA016672; United States / NIDDK NIH HHS / DK / R21 DK068414; United States / NCI NIH HHS / CA / CA16672; United States / NIDDK NIH HHS / DK / R01 DK052067; United States / NIDDK NIH HHS / DK / R01 DK052067-11; United States / NIDDK NIH HHS / DK / 5R21DK068414; United States / NCI NIH HHS / CA / P20 CA101936; United States / NIAAA NIH HHS / AA / R01 AA020822; United States / NIDDK NIH HHS / DK / DK052067
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS268542; NLM/ PMC3050544
  •  go-up   go-down


11. González-Peramato P, Jiménez-Heffernan JA, López-Ferrer P, Vicandi B, Viguer JM: Fine needle aspiration cytology of dedifferentiated acinic cell carcinoma of the parotid gland: a case report. Acta Cytol; 2006 Jan-Feb;50(1):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of dedifferentiated acinic cell carcinoma of the parotid gland: a case report.
  • BACKGROUND: Dedifferentiation of acinic cell carcinoma (ACC) to undifferentiated carcinoma occurs rarely and entails a poor prognosis.
  • They were distributed in small and larger, branching groups with acinic morphology.
  • A cytologic diagnosis of "salivary carcinoma with coexisting areas of acinic cell differentiation and high grade, undifferentiated carcinoma" was given.
  • Histopathology revealed a well-differentiated ACC with areas of high grade undifferentiated carcinoma (dedifferentiated ACC).
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Acinar Cell / diagnosis. Epithelial Cells / pathology. Parotid Gland / pathology. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biopsy, Fine-Needle. Cell Differentiation. Humans. Male

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514851.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Xu X, Ehdaie B, Ohara N, Yoshino T, Deng CX: Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice. Oncogene; 2010 Feb 4;29(5):674-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice.
  • Mutations of SMAD4/DPC4 are found in about 60% of human invasive pancreatic ductal adenocarcinomas (PDACs); yet, the manner in which SMAD4 deficiency enhances tumorigenesis remains elusive.
  • We showed that the absence of Smad4 alone did not trigger pancreas tumor formation; however, it increased the expression of an inactivated form of Pten, suggesting a role of Pten in preventing Smad4-/- cells from undergoing malignancy.
  • We showed that Pten deficiency initiated widespread premalignant lesions, and a low tumor incidence that was significantly accelerated by Smad4-deficiency.
  • The absence of Smad4 in a Pten-mutant background enhanced cell proliferation and triggered transdifferentiation from acinar, centroacinar and islet cells, accompanied by activation of Notch1 signaling.
  • We showed that all tumors developed in the Smad4/Pten-mutant pancreas exhibited high levels of pAKT and mTOR, and that about 50 and 83% of human pancreatic cancers examined showed increased pAKT and pmTOR, respectively.
  • Besides the similarity in gene expression, the pAKT and/or pmTOR-positive human PDACs and mouse pancreatic tumors also shared some histopathological similarities.
  • These observations indicate that Smad4/Pten-mutant mice mimic the tumor progression of human pancreatic cancers that are driven by activation of the AKT-mTOR pathway, and uncovered a synergistic action of Smad4 and Pten in repressing pancreatic tumorigenesis.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. PTEN Phosphohydrolase / metabolism. Pancreatic Neoplasms / metabolism. Signal Transduction / physiology. Smad4 Protein / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Transdifferentiation / physiology. Gene Expression. Genotype. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Knockout. Phenotype. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. TOR Serine-Threonine Kinases


13. Leivo I, Jee KJ, Heikinheimo K, Laine M, Ollila J, Nagy B, Knuutila S: Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation. Cancer Genet Cytogenet; 2005 Jan 15;156(2):104-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation.
  • Gene expression profiles were studied in 13 cases of salivary gland carcinoma including mucoepidermoid carcinoma (MEC), acinic cell carcinoma (ACC), and salivary duct carcinoma (SDC) using a cDNA array.
  • Only 5 genes were overexpressed in all carcinomas including fibronectin 1 (FN1), tissue metalloproteinase inhibitor 1 (TIMP1), biglycan (BGN), tenascin-C (HXB), and insulin-like growth factor binding protein 5 (IGFBP5), whereas 16 genes were underexpressed.
  • The small number of similarly deregulated genes in these carcinoma entities suggests an extensive genetic variation between them.
  • This result agrees with the great histopathological diversity of different entities of salivary gland carcinoma.
  • Furthermore, diversity in gene expression between the carcinoma types was identified also by hierarchical clustering.
  • Each carcinoma entity was clustered together but MEC, SDC, and ACC were separated from each other.
  • In MEC, overexpressed genes included those of cell proliferation (IL-6 and SFN) and cell adhesion (SEMA3F and COL6A3), whereas many underexpressed genes were related to DNA modification (NTHL1 and RBBP4).
  • Apoptosis-related genes CASP10 and MMP11 were overexpressed in SDC, in accordance with the typical tumor necrosis seen in this entity.
  • An intermediate filament protein of basal epithelial cells, cytokeratin 14 (KRT14) was clearly differently expressed between the 3 types of carcinoma, and can be used as an aid in their differential diagnosis.


14. Gologan A, Bastacky S, McHale T, Yu J, Cai C, Monzon-Bordonaba F, Dhir R: Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues. Am J Surg Pathol; 2005 Nov;29(11):1435-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMACR expression in the prostate has been investigated primarily in patients, in an older age group, treated for prostatic carcinoma and benign prostatic hypertrophy.
  • Semi-quantitative analysis of staining in acinar cells was used to generate a composite score (CS) [Sigma(% area x intensity)] for each case.
  • Acinar cells showed granular cytoplasmic staining.
  • Most cases in the control set of prostatic adenocarcinoma cases showed moderate to strong staining.
  • However, AMACR staining should be interpreted with caution and the diagnosis of PIN or prostate cancer should be rendered only with convincing histologic evidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224209.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA 86735-05; United States / NCI NIH HHS / CA / U01-CA 88110-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


15. Leite KR, Mitteldorf CA, Srougi M, Dall'oglio MF, Antunes AA, Pontes J Jr, Camara-Lopes LH: Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. Ann Diagn Pathol; 2008 Aug;12(4):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are some unusual histologic variants of prostate carcinoma, including mucinous, signet-ring cells, and ductal carcinomas that can metastasize in a problematic way and simulate lung, colorectal, or bladder primaries.
  • Our aim is to study the profile of expression of Cdx2, thyroid transcription factor 1 (TTF1), and cytokeratin 20 (CK20) in prostate cancer with unusual histologic finding.
  • Twenty-nine prostate adenocarcinomas with unusual histologic findings were submitted to immunohistochemistry with prostate-specific antigen (PSA), CK20, Cdx2, and TTF1 antibodies.
  • There were 7 mucinous, 5 ductal, 2 signet-ring cells, and 15 usual acinar adenocarcinomas with focal mucinous differentiation.
  • To compare the results with usual acinar adenocarcinomas, we studied 10 primary and their respective lymph node metastases in a tissue microarray, 2 unusual metastatic adenocarcinomas, and 6 usual acinar high-grade carcinomas.
  • For tumors with special histologic finding, Cdx2 was expressed by 9 (31.0%) mucinous, signet-cell, or with focal mucinous differentiation.
  • Thyroid transcription factor 1 was moderately positive in mucinous differentiation areas of 2 (6.9%) adenocarcinomas.
  • Cytokeratin 20 was expressed by 9 (31.0%) tumors, among them, 3 ductal adenocarcinomas.
  • Prostate-specific antigen was positive in 28 (96.6%) cases and negative in 1 ductal adenocarcinoma.
  • There was only 1 worrisome ductal adenocarcinoma that was strongly CK20 positive and PSA negative.
  • Almost one third of mucinous prostate carcinomas express Cdx2.
  • Cytokeratin 20 can be positive also in one third of prostate carcinomas, especially the ductal type.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Transcription Factors / biosynthesis


16. Furonaka O, Takeshima Y, Awaya H, Kushitani K, Kohno N, Inai K: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int; 2005 Jun;55(6):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.
  • The methylation status of the MGMT gene was investigated by methylation-specific polymerase chain reaction (PCR) and expression status was investigated by immunohistochemistry in 70 cases of pulmonary squamous cell carcinoma (pulmonary SqCC), including 23 cases of the central type and 47 cases of the peripheral type, and in 53 cases of the peripheral type of pulmonary adenocarcinoma (AC).
  • The frequency of MGMT methylation was 36% in SqCC and 42% in AC.
  • Cases with MGMT methylation correlated significantly with T factor in SqCC (P = 0.047) and AC (P = 0.03).
  • In AC with mixed subtypes showing MGMT methylation, the level of MGMT expression in the bronchioloalveolar carcinoma (BAC) area (non-invasive status) was significantly higher than that in the papillary or acinar AC area (invasive status; P = 0.0002).
  • This trend was not found in AC with mixed subtypes showing no MGMT methylation (P = 0.10).
  • These findings suggest that MGMT inactivation is an event that occurs in the late carcinogenic process in SqCC and AC, and that AC progress from non-invasive status to invasive status with MGMT inactivation induced by the promoter DNA methylation.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation. Lung Neoplasms / pathology. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943786.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


17. Bhattacharyya N, Fried MP: Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol; 2005 Jan-Feb;26(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of survival in parotid gland carcinoma: a population-based study.
  • Kaplan-Meier survival analysis was conducted for the most common tumor histologies.
  • Subset analysis was conducted for mucoepidermoid carcinoma according to grade.
  • Mean tumor size at diagnosis was 2.7 cm; 38.0% of patients had extraglandular extension of the tumor, 26.8% of patients had positive nodal disease, and 59.4% of patients received radiation therapy.
  • Tumor histology did predict survival, with squamous cell carcinoma and acinar cell carcinoma exhibiting the poorest and best survivals, respectively.
  • Stratified Cox proportional hazards modeling revealed that increasing age, tumor size, grade, extraglandular extension, and nodal positivity significantly negatively influenced survival (all P<or=.001); radiation therapy conferred a survival benefit (P=.090), whereas gender did not significantly affect survival.
  • Increasing tumor grade, nodal disease, and extraglandular extension carried particularly high hazards ratios.
  • Patients with multiple poor prognostic features such as extraglandular extension, aggressive tumor histologies, and nodal disease will exhibit poorer survivals and may be candidates for more aggressive treatment protocols.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Parotid Neoplasms / mortality
  • [MeSH-minor] Age Factors. Carcinoma, Acinar Cell / mortality. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Mucoepidermoid / mortality. Female. Humans. Male. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. SEER Program. Sex Factors. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15635580.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Suh SI, Seol HY, Kim TK, Lee NJ, Kim JH, Kim KA, Woo JS, Lee JH: Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of the head and neck: radiologic-pathologic correlation.
  • OBJECTIVE: To describe and correlate the imaging and pathologic findings of acinic cell carcinoma (ACC) in the head and neck.
  • A parapharyngeal lesion was cystic mass with mural nodule, and a submandibular and a palate tumor were cystic lesions on CT.
  • CONCLUSION: Although ACC appears to have nonspecific imaging findings, familiarity with some imaging features can be helpful for differential diagnosis of head and neck tumors.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Head and Neck Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Child, Preschool. Diagnosis, Differential. Female. Hemorrhage / pathology. Hemorrhage / radiography. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Necrosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Palatal Neoplasms / pathology. Palatal Neoplasms / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiography. Retrospective Studies. Submandibular Gland Neoplasms / pathology. Submandibular Gland Neoplasms / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665697.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chilosi M, Murer B: Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med; 2010 Jan;134(1):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy.
  • CONTEXT: Lung cancer is one of the most frequent and lethal malignant neoplasms, but knowledge regarding the molecular basis of its pathogenesis is far from complete due to the striking diversity of different forms.
  • The current lung cancer classification (World Health Organization 2004) can efficiently distinguish clinically relevant major subtypes (small cell and non-small cell carcinomas), but its results are partly inadequate when facing prognostic and therapeutic decisions for non-small cell carcinomas, especially for the group of tumors classified as adenocarcinoma.
  • Lung adenocarcinoma comprises a heterogeneous group of tumors characterized by diverse morphologic features and molecular pathogenesis.
  • The category of mixed adenocarcinomas includes most adenocarcinomas (approximately 80%) and, according to World Health Organization criteria, is defined by the occurrence of a mixed array of different patterns (acinar, papillary, bronchioloalveolar, solid with mucin).
  • The histologic recognition of mixed adenocarcinoma is subjective and cannot consistently discriminate between responders and nonresponders to new targeted therapies (eg, tyrosine kinase inhibitors).
  • In this evolving scenario, pathologists face new challenging diagnostic roles that include not only the precise morphologic definition of carcinoma subtypes but also their molecular characterization.
  • OBJECTIVE: To use a comprehensive critical analysis reconciling the overwhelming variety of biologic, morphologic, molecular, and clinical data to define new classification schemes for lung adenocarcinoma.
  • CONCLUSIONS: A new classification approach should redefine lung adenocarcinoma heterogeneity reconciling classic morphology, immunophenotypic and molecular features of neoplastic cells, and also relevant information provided by stem cell biology.
  • This approach, which has been already successfully applied in World Health Organization classification of other tumors, could improve the recognition of new reproducible profiles for adenocarcinomas, more closely and reproducibly related to clinical features and response to specific therapies, limiting the use of "wastebasket" categories such as mixed adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cell Differentiation. Drug Therapy. Humans. Stem Cells / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073606.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Most of these tumors are capable of differentiating along both epithelial and myoepithelial lines, but the amount of each lineage-component varies from case to case, contributing to diagnostic difficulties.
  • Well established examples of this group include pleomorphic adenoma, adenomyoepithelioma, and adenoid cystic carcinoma.
  • Key examples include mucoepidermoid carcinoma and acinic cell carcinoma.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Ghossein RA, Lee NY: Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer; 2009 May 15;115(10):2128-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.
  • BACKGROUND: To the authors' knowledge, the indications for adjuvant treatment in acinic cell carcinoma (AciCC) of the parotid gland have not been elucidated to date.
  • Five-year estimates of disease-free survival (DFS), overall survival (OS), and local control were 85%, 90%, and 90%, respectively.
  • If high-grade tumors were defined on the basis of high mitotic activity (>2 mitoses/10 HPF) and/or tumor necrosis, high-grade carcinomas had a significantly lower DFS and OS (P = .001).
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Facial Nerve Injuries / etiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309749.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Montironi R, Vela Navarrete R, Lopez-Beltran A, Mazzucchelli R, Mikuz G, Bono AV: Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Arch; 2006 Jul;449(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphological findings of the needle biopsy may be placed into one of the following five categories: prostate cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, inflammation, and benign prostatic tissue.
  • While the prime goal of the biopsy is to diagnose prostatic adenocarcinoma, once carcinoma is detected, further descriptive information regarding the type, amount of cancer, and grade forms the cornerstone for contemporary management of the patient and for assessment of the potential for local cure and the risk for distant metastasis.
  • The information provided in the needle biopsy report regarding the attributes of carcinoma is used depending on the individual patient's medical condition and preference and on the treating physician's evaluation to determine whether any form of treatment is indicated and, if so, the type of therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / trends. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2000 Apr;37(4):404-12 [10765070.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Arch Pathol Lab Med. 1995 May;119(5):444-7 [7748073.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):887-91 [7543443.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):82-93 [16019760.001]
  • [Cites] BJU Int. 2006 Mar;97(3):492-7 [16469014.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] J Urol. 2002 Jun;167(6):2440-2 [11992053.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):516-20 [11792909.001]
  • [Cites] Hum Pathol. 2001 Aug;32(8):828-33 [11521227.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1203-8 [14501725.001]
  • [Cites] Cytometry. 1993;14(5):497-500 [8354122.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Urology. 2004 Jun;63(6):1105-10 [15183961.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):589-95 [8273267.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1146-52 [15877724.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):442-50 [12219787.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):41-5 [8841465.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Pathology. 2003 Dec;35(6):472-9 [14660096.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):424-5 [9563798.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):20-33 [16019757.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1884-93 [12673714.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2344-50 [14635068.001]
  • [Cites] J Urol. 2004 Mar;171(3):1093-7 [14767278.001]
  • [Cites] Cancer. 1991 Jun 15;67(12 ):2949-58 [1710531.001]
  • [Cites] Urology. 2003 Mar;61(3):589-95 [12639653.001]
  • [Cites] J Urol. 2004 Mar;171(3):1122-7 [14767284.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):752-7 [2386903.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):266-8 [8135180.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1186-91 [11106075.001]
  • [Cites] J Urol. 2002 Nov;168(5):1994-9 [12394693.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Eur Urol. 1993;23 Suppl 2:64-76 [7685705.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] BMJ. 2001 Feb 17;322(7283):378-9 [11179143.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] J Urol. 2003 Jun;169(6):2136-41 [12771735.001]
  • [Cites] Urol Int. 2003;70(4):297-302 [12740495.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S31-7 [7524305.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):8-19 [16019756.001]
  • [Cites] Urology. 1999 Apr;53(4):752-6 [10197851.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1511-21 [9137077.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1050-4 [7487406.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):177-81 [15245810.001]
  • [Cites] J Urol. 2003 Nov;170(5):1792-7 [14532778.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):477-8 [10757394.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Pathol Res Pract. 1993 Jun;189(5):542-8 [7690954.001]
  • [Cites] Urology. 1996 Jul;48(1):47-57 [8693651.001]
  • [Cites] Arch Ital Urol Androl. 2005 Mar;77(1):31-6 [15906787.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Urol. 1997 Apr;157(4):1301-3 [9120926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1087-92 [9719119.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2196-204 [11391602.001]
  • [Cites] Hum Pathol. 1993 Nov;24(11):1159-67 [8244315.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):94-110 [16019761.001]
  • [Cites] Urology. 1997 Jun;49(6):857-62 [9187691.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):223-8 [9930144.001]
  • (PMID = 16633784.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 81
  •  go-up   go-down


23. Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA: A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med; 2007 Jul;131(7):1103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
  • CONTEXT: Prostatic adenocarcinoma growing within acinar-ductal spaces (intraductal carcinoma) in contrast to high-grade prostatic intraepithelial neoplasia (HG-PIN) impacts negatively on patient outcome.
  • OBJECTIVE: To define intraductal carcinoma of the prostate (IDC-P) with major and minor diagnostic criteria that clearly separate it from HG-PIN.
  • DATA SOURCES: We reviewed all published data referring to intraductal spread of prostate carcinoma.
  • Articles discussing endometrial, endometrioid, and ductal carcinoma are included.
  • CONCLUSIONS: Intraductal carcinoma of the prostate as defined by major criteria that include enlarged gland structures, neoplastic cells spanning the gland lumen, central comedonecrosis, and further supported by minor diagnostic criteria including molecular biological markers, separate this entity from HG-PIN.
  • Despite its perimeter basal cells, IDC-P should be interpreted as biologically equivalent to Gleason pattern 4 or 5 adenocarcinoma.
  • Several hypotheses are proposed as to the evolution of IDC-P, which is almost always a late event in prostate carcinoma progression.
  • Diagnosis of IDC-P on needle biopsy should prompt therapeutic intervention rather than surveillance or repeat biopsy, as is the case for HG-PIN.
  • [MeSH-major] Carcinoma, Intraductal, Noninfiltrating / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2008 Mar;132(3):319-20; author reply 320-1 [18318572.001]
  • (PMID = 17616999.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


24. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S: Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol; 2010 Aug;31(4):351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall, 70 patients treated with second-line therapy for advanced disease were included; 94% had distant metastases at treatment initiation.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Acinar Cell / blood. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / pathology. Female. Humans. Kinetics. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 1996 Dec 30;15(24):2797-812 [8981687.001]
  • [Cites] Onkologie. 2003 Oct;26(5):462-7 [14605463.001]
  • [Cites] Oncology. 2007;73(1-2):41-51 [18334830.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):58-68 [8453928.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:145-9 [10436809.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] Oncology. 2008;75(1-2):120-6 [18784438.001]
  • [Cites] Oncology. 2007;73(3-4):221-7 [18424886.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):132-8 [18249033.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):547-50 [11801751.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1292-7 [18700899.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):41-50 [18240999.001]
  • [Cites] World J Surg. 2009 Apr;33(4):716-22 [19082654.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2630-9 [19353729.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):195-9 [15999098.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):755-61 [18845521.001]
  • (PMID = 20480409.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 9007-41-4 / C-Reactive Protein; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


25. Perez N, Castillo M, Santos Y, Truan D, Gutierrez R, Franco A, Palacin A, Bombi JA, Campo E, Fernandez PL: Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings. Virchows Arch; 2005 May;446(5):511-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings.
  • Carcinosarcomas (CS) of the prostate are very uncommon neoplasms defined by the admixture of malignant epithelial and mesenchymal components.
  • We describe here two new examples of CS in two patients aged 66 and 77 years, the first without previous history of prostate adenocarcinoma and the second with a 5-year history of acinar type prostate adenocarcinoma.
  • The diagnosis of CS was made on the cystoprostatectomy specimen in the first case and transurethral resection in the second case.
  • Both biphasic tumours exhibited papillary areas of ductal differentiation and conventional adenocarcinoma in the epithelial component, as well as malignant fibrous histiocytoma and angiosarcomatous areas in the first case and solid, poorly differentiated epithelial areas with neuroendocrine features in the second case.
  • Immunohistochemistry revealed over-expression of c-erb B2 in the papillary epithelial component of both cases, whereas the solid undifferentiated epithelial areas in the second patient expressed c-kit, CD10 and synaptophysin, thus conforming a very undifferentiated cell population.
  • The clinical course of the cases was divergent; the first patient is free of disease after radical surgery and adjuvant therapy and the other died 5 months after the diagnosis of CS, having already developed liver metastases.
  • [MeSH-major] Carcinosarcoma / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1991 Nov;146(5):1370-3 [1942296.001]
  • [Cites] Prostate. 2003 Sep 1;56(4):250-5 [12858352.001]
  • [Cites] Am J Clin Pathol. 1989 Aug;92(2):131-9 [2474243.001]
  • [Cites] J Urol. 1979 Nov;122(5):709-11 [501837.001]
  • [Cites] Urol Int. 1992;48(1):105-7 [1376007.001]
  • [Cites] Acta Pathol Jpn. 1993 Apr;43(4):209-14 [8493872.001]
  • [Cites] Pathol Res Pract. 2000;196(8):569-72 [10982020.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2275-82 [2317815.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):342-9 [8494104.001]
  • [Cites] J Urol. 2002 Jul;168(1):315-22 [12050563.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1035-42 [8625205.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Tech Urol. 2001 Dec;7(4):294-5 [11763492.001]
  • [Cites] Urology. 1981 Jul;18(1):85-8 [7257048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15152-7 [8986779.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):101-8 [12242724.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):374-82 [10705818.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1650-5 [12365012.001]
  • [Cites] Urology. 1992 Oct;40(4):376-80 [1329302.001]
  • [Cites] Acta Pathol Jpn. 1985 Mar;35(2):481-7 [4024945.001]
  • [Cites] Urol Int. 1997;59(1):50-2 [9313326.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2676-82 [1571897.001]
  • [Cites] Prostate. 2001 May 15;47(3):164-71 [11351345.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):108-13 [12588610.001]
  • [Cites] J Urol. 1981 Mar;125(3):436-8 [7206104.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):365-74 [10809354.001]
  • [Cites] Arch Esp Urol. 1992 Oct;45(8):779-82 [1466577.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):998-1001 [2201434.001]
  • [Cites] J Urol. 1967 Mar;97(3):518-22 [6019611.001]
  • [Cites] J Urol. 1970 Jan;103(1):80-3 [5415727.001]
  • [Cites] Eur Urol. 1986;12(6):441-2 [3816901.001]
  • [Cites] World J Urol. 1999 Oct;17 (5):316-8 [10552151.001]
  • [Cites] Hum Pathol. 2003 May;34(5):450-6 [12792918.001]
  • (PMID = 15821929.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers; 0 / CAM 5.2 antigen; 68238-35-7 / Keratins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.21.77 / Prostate-Specific Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


26. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y: let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer; 2007 Dec;58(3):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis.
  • In this study, we examined 15 early bronchioloalveolar carcinomas (BACs), usually considered as adenocarcinomas in situ, as well as 26 well-differentiated and 25 less-differentiated invasive adenocarcinomas, to assess the association between tumor progression and let-7 expression levels.
  • Additionally, we investigated 47 invasive lung adenocarcinomas for EGFR and KRAS mutations and correlations with let-7 levels.
  • Relative to the corresponding normal lung tissue, reduced let-7 expression was observed in 13 of 15 BACs (87%) and totally in 52 of the 66 adenocarcinomas (79%), suggesting a link with early occurrence in carcinogenesis.
  • On classification of adenocarcinomas into two groups according to let-7 expression, no prognostic or genetic differences were observed.
  • Interestingly, some differences between histological subtypes were observed, such as lower let-7 expression levels in acinar adenocarcinomas and mucinous BACs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Gene Expression Regulation, Neoplastic / genetics. MicroRNAs / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2008 May;60(2):307 [18395292.001]
  • (PMID = 17728006.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


27. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


28. Ando K, Ohkuni Y, Kaneko N, Narita M: Spontaneous rupture of the splenic metastasis in acinar cell carcinoma. Pancreas; 2009 Oct;38(7):836-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous rupture of the splenic metastasis in acinar cell carcinoma.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Pancreatic Neoplasms / pathology. Spleen / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Rupture, Spontaneous. alpha 1-Antichymotrypsin / metabolism. alpha 1-Antitrypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893460.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha 1-Antichymotrypsin; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


29. Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M: Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol; 2005 Jun;18(6):779-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma.
  • The non-neoplastic pancreatic parenchyma adjacent to infiltrating ductal adenocarcinoma demonstrates inflammation, fibrosis, acinar cell loss and small duct-like metaplasia of acinar cells.
  • Similar morphologic changes are also observed in the setting of chronic pancreatitis.
  • To better understand the pancreatic acinar responses to infiltrating pancreatic ductal adenocarcinoma, we characterized gene expression patterns of pancreatic acinar tissue adjacent to infiltrating pancreatic ductal adenocarcinomas and compared them to gene expression patterns of acinar tissue affected by chronic pancreatitis as well as to those of normal pancreatic acini.
  • Fresh-frozen pancreatic acinar tissue was microdissected from nine patients (three with pancreatic cancer, three with chronic pancreatitis, three with normal pancreata) using laser capture microdissection, and extracted RNA from each microdissection was subjected to two rounds of linear amplification and hybridized to oligonucleotide microarrays.
  • A total of 20 genes was found to be overexpressed in peritumoral acinar tissue compared to normal acinar tissue and to acini affected by chronic pancreatitis.
  • Serum HC gp-39 protein levels were significantly higher in patients with pancreatic cancer and in those with chronic pancreatitis than in controls without pancreatic disease.
  • Our results demonstrate some of the molecular alterations in acinar cells that occur in response to adjacent infiltrating pancreatic ductal adenocarcinoma and reveal that such alterations can provide a rich source of markers of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Gene Expression Profiling. Pancreas / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791284.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; 0 / RNA, Neoplasm
  •  go-up   go-down


30. Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, Virtaniemi J, Hinkka S, Grénman R: Salivary gland cancer in Finland 1991--96: an evaluation of 237 cases. Acta Otolaryngol; 2005 Feb;125(2):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: In this material consisting of various salivary gland carcinomas, stage I, male gender and age were the most powerful predictors of patient outcome.
  • The commonest tumor location was the parotid gland (n = 152; 64%), followed by the minor salivary glands (n =46; 19%), the submandibular gland (n =38; 16%) and the sublingual gland (n = 1; 0.4%).
  • The most frequent histological types of SGC were adenoid cystic carcinoma (n =65; 27%), mucoepidermoid carcinoma (n =45; 19%) and acinic cell carcinoma (n =41; 17%).
  • Of the commonest tumor types, the best 5-year relative survival rate was for patients with acinic cell carcinoma (96%), followed by those with mucoepidermoid (79%) and adenoid cystic carcinoma (74%).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / epidemiology. Carcinoma / mortality. Carcinoma / surgery. Female. Finland / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Parotid Neoplasms / epidemiology. Parotid Neoplasms / mortality. Parotid Neoplasms / surgery. Population Surveillance / methods. Survival Rate

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880955.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


31. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI: Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol; 2008 Mar;32(3):461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
  • Aberrant diffuse expression of p63 in prostate carcinoma cells is a rare and poorly understood phenomenon.
  • Needle biopsy cases ranged from Gleason patterns 3 to 5 with tumor identified on one or more cores, ranging from a minute focus to 80% of the core.
  • In all 8 radical prostatectomies p63 positive cancer was present, with in 2/8 cases both p63 positive cancer and usual p63 negative acinar prostate cancer.
  • In all 8 cases, the tumors were organ confined with negative margins and there was no seminal vesicle involvement or lymph node metastasis.
  • The presence of p63 positive atypical glands with an infiltrative pattern and perineural invasion on radical prostatectomy confirmed the needle biopsy diagnosis of carcinoma.
  • Rarely, prostate cancer can aberrantly express diffuse p63 staining in a nonbasal cell distribution leading to the erroneous diagnosis of atrophy or atypical basal cell proliferation.
  • The diagnosis of prostate cancer is based on the morphology and confirmed by the absence of high molecular weight cytokeratin staining and positivity for alpha-methylacyl-CoA racemase in the atypical glands.
  • Pathologists need to be aware of this rare and unusual phenomenon, which is a potential pitfall in prostate cancer diagnosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biopsy, Needle. Membrane Proteins / analysis. Prostatectomy. Prostatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300803.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


32. Meer S, Altini M: CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology; 2007 Jul;51(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumours included pleomorphic adenoma (n = 24), myoepithelioma (n = 9), papillary cystadenoma (n = 3), oncocytoma (n = 2), adenoid cystic carcinoma (n = 22), mucoepidermoid carcinoma (n = 21), polymorphous low-grade adenocarcinoma (n = 21), carcinoma ex-pleomorphic adenoma (n = 11), acinic cell carcinoma (n = 17), epimyoepithelial carcinoma (n = 7), oncocytic carcinoma (n = 3), hyalinizing clear cell carcinoma (n = 1), papillary cystadenocarcinoma (n = 1), salivary duct carcinoma (n = 3), adenocarcinoma (not otherwise specified) (n = 4) and squamous carcinoma (n = 4).
  • Squamous carcinoma showed negative CK7/20 immunoexpression.
  • CONCLUSIONS: Although the CK7/20 immunoprofile is not useful in distinguishing the various types of salivary gland neoplasms or between benign and malignant salivary gland tumours, it may facilitate differentiation of primary salivary gland neoplasia from metastatic tumours and squamous carcinoma, and the diagnosis of metastatic salivary gland tumours.
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Salivary Glands / metabolism. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593078.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


33. Salgarelli AC, Capparè P, Bellini P, Collini M: Usefulness of fine-needle aspiration in parotid diagnostics. Oral Maxillofac Surg; 2009 Dec;13(4):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This review presents an analysis of the usefulness of FNA in differential diagnosis of parotid pathologies.
  • FNA is notoriously unreliable in recognising the malignant nature of parotid carcinoma providing its precise classification and establishing its grade.
  • A few malignant neoplasms are particularly prone to diagnostic error: acinic cell carcinoma is frequently interpreted as benign, and low-grade lymphomas are often discounted as inflammatory processes.
  • For planning the extent of surgery of malignant parotid tumours, the histological subtype and/or grade should be determined; therefore, a histological diagnosis by frozen section analysis is required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Oct 15;72(8):2306-11 [8402443.001]
  • [Cites] Laryngoscope. 2006 Apr;116(4):534-40 [16585855.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] J Pak Med Assoc. 2004 Dec;54(12):617-9 [16104489.001]
  • [Cites] Head Neck. 2005 Mar;27(3):217-23 [15672359.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):62-6 [16552260.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):163-6 [10450099.001]
  • [Cites] Cytopathology. 1995 Oct;6(5):285-300 [8785366.001]
  • [Cites] Ear Nose Throat J. 1994 Jun;73(6):377-80 [8076536.001]
  • [Cites] Head Neck. 2002 Feb;24(2):191-7 [11891949.001]
  • [Cites] ANZ J Surg. 2005 Mar;75(3):144-6 [15777394.001]
  • [Cites] Laryngoscope. 2004 Apr;114(4):789 [15064645.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1318-22 [16303681.001]
  • [Cites] Acta Cytol. 1992 May-Jun;36(3):353-63 [1580118.001]
  • [Cites] Semin Surg Oncol. 1991 Jan-Feb;7(1):20-4 [2003181.001]
  • [Cites] Br J Surg. 1989 Dec;76(12 ):1273-4 [2605471.001]
  • [Cites] Eur J Surg Oncol. 1998 Jun;24(3):180-3 [9630856.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):615-9 [1730113.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):720-3 [12874071.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Jun;102(6):483-5 [8347239.001]
  • [Cites] Ann Surg. 1930 Aug;92(2):169-81 [17866350.001]
  • [Cites] Acta Cytol. 1997 Sep-Oct;41(5):1421-5 [9305379.001]
  • [Cites] J R Coll Surg Edinb. 2001 Apr;46(2):91-5 [11329749.001]
  • [Cites] Arch Pathol Lab Med. 1987 Apr;111(4):346-53 [3030228.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1610-3 [14583757.001]
  • [Cites] Surg Gynecol Obstet. 1966 Apr;122(4):811-6 [4286811.001]
  • [Cites] Diagn Cytopathol. 2000 Mar;22(3):139-46 [10679992.001]
  • [Cites] Acta Otolaryngol. 1964 Dec;58:471-84 [14253066.001]
  • [Cites] Sao Paulo Med J. 1999 Nov 4;117(6):233-7 [10625885.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 May;138(5):601-5 [18439465.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Mar;132(3):387-91 [15746848.001]
  • [Cites] J Laryngol Otol. 2005 Apr;119(4):289-92 [15949083.001]
  • [Cites] Med Princ Pract. 2004 Mar-Apr;13(2):95-106 [14755143.001]
  • [Cites] Laryngoscope. 2001 Sep;111(9):1551-7 [11568593.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):26-31 [15628905.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Feb;101(2 Pt 1):185-8 [1739267.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Dec;139(6):811-5 [19041508.001]
  • [Cites] Ear Nose Throat J. 2005 Aug;84(8):518, 520-2, 524 [16220858.001]
  • [Cites] Laryngoscope. 1991 Mar;101(3):245-9 [2000011.001]
  • [Cites] Surgeon. 2005 Apr;3(2):67-72 [15861939.001]
  • [Cites] Pathol Biol. 1959 Apr;7(7-8):785-91 [13667300.001]
  • [Cites] Otolaryngol Clin North Am. 1998 Oct;31(5):815-22 [9735109.001]
  • [Cites] Cancer. 1998 Jun 25;84(3):153-9 [9678729.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):170-3 [10450101.001]
  • [Cites] Acta Cytol. 1985 Jul-Aug;29(4):503-12 [2992196.001]
  • [Cites] Cancer. 2004 May 1;100(9):1876-83 [15112268.001]
  • (PMID = 19821124.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 51
  •  go-up   go-down


34. Wang Y, Liu XG, Liang MZ, Qin PX, Lin YJ, Yi XP: [Correlation of early phase contrast enhancement of multi-detector row computed tomography to tumor stroma of nodular solid lung adenocarcinoma]. Ai Zheng; 2008 Nov;27(11):1190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of early phase contrast enhancement of multi-detector row computed tomography to tumor stroma of nodular solid lung adenocarcinoma].
  • BACKGROUND & OBJECTIVE: Dynamic enhanced multi-detector row CT (MDCT) has been used in differential diagnosis of pulmonary nodules, but its mechanism was unclear yet.
  • This study was to evaluate the correlations of early phase enhancement of MDCT to proportion and distribution of stroma in solid lung adenocarcinoma.
  • METHODS: A total of 31 patients with lung adenocarcinoma underwent routine contrast-enhanced MDCT.
  • Tumor morphology was observed with HE staining.
  • RESULTS: The proportion of invasive stroma in tumors was correlated positively to CT enhancement value (r=0.483, P=0.006).
  • Most acinar adenocarcinomas had net enhancement of > 20 Hu, which was significantly higher than that of solid adenocarcinomas with mucin subtype (P=0.005).
  • CONCLUSIONS: Extent and pattern of CT enhancement of solid lung adenocarcinoma nodules reflect the proliferation and distribution of stroma, respectively.
  • It is helpful to comprehend some false negative on CT enhancement by adequately understanding of the pathologic features of different subtypes of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography. Solitary Pulmonary Nodule / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiography. Adult. Aged. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / radiography. Female. Humans. Male. Microvessels / pathology. Microvessels / radiography. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiographic Image Enhancement

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000452.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Fellegara G, D'Adda T, Pilato FP, Froio E, Ampollini L, Rusca M, Rindi G: Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma. Virchows Arch; 2008 Jul;453(1):107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.
  • Combined nonneuroendocrine-neuroendocrine lung tumors are relatively infrequent and little is known as for their genetic basis.
  • At histological examination, the tumor showed two components.
  • The main part was an adenocarcinoma of the acinar type.
  • The second part showed morphological and immunohistochemical phenotype of a neuroendocrine carcinoma composed of a small cell lung carcinoma and a large cell neuroendocrine carcinoma.
  • The aim of our study was to investigate the genetic relationship between neuroendocrine and nonneuroendocrine tumor components.
  • Microallelotyping revealed a common genetic profile in the different tumor areas.
  • These findings support the true combined nature of this exocrine-neuroendocrine carcinoma of the lung and suggest a common monoclonal origin from a pluripotent epithelial (alveolar or bronchial) precursor cell for the two different tumor components.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1998 Oct;29(10):1145-9 [9781656.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):918-25 [11567220.001]
  • [Cites] Lung Cancer. 1998 Jul;21(1):53-8 [9792054.001]
  • [Cites] Histopathology. 1986 May;10(5):461-75 [3013746.001]
  • [Cites] Arch Pathol Lab Med. 2002 Apr;126(4):437-41 [11900568.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):569-79 [2987102.001]
  • [Cites] Lab Invest. 2003 Jul;83(7):963-71 [12861036.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):175-82 [11957142.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Jan;7(1):77-86 [17187486.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Nov;22(5):701-7 [12414033.001]
  • [Cites] Pathologica. 2001 Jun;93(3):216-20 [11433616.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):795-805 [15578070.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1184-97 [12218575.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1714-9 [17784875.001]
  • [Cites] Chest. 2001 Jan;119(1):14-8 [11157578.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):600-7 [10091733.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):395-402 [17707945.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):558-63 [7837389.001]
  • [Cites] Hum Pathol. 1992 May;23(5):520-8 [1314777.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):414-22 [18204434.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1059-63 [11679939.001]
  • (PMID = 18551311.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


36. Gamal G, Sano T, Sakurai S, Kawashima O, Sugano M, Nakajima T: Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis. Pathol Int; 2007 Dec;57(12):765-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis.
  • To re-evaluate adenocarcinoma, mixed subtypes (ADMIX) of the lung, a total of 201 cases were classified into three main subgroups according to the most differentiated histological growth pattern; namely bronchioloalveolar carcinoma (BAC)-mixed, which was the most predominant (73.1%), papillary (PAP)-mixed (21.9%), and acinar-mixed (5%).
  • Hierarchical clustering analysis was separately applied to the immunohistochemical results of ADMIX and ADMIX subgroups, and it was found that most acinar-mixed cases were placed in a separate cluster, while the BAC-mixed and PAP-mixed failed to form significant independent clusters.
  • The antibody clustering profile for the acinar-mixed was clearly different from that for the BAC-mixed or PAP-mixed, but the PAP-mixed shared a dendrogram profile with the other two subgroups.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cluster Analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988277.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D: Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? BJU Int; 2007 Apr;99(4):780-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
  • OBJECTIVE: To determine if atypical small acinar proliferation (ASAP) represents minimally sampled prostate cancer not fully evaluated on a biopsy or a distinct pathological entity, by examining prostates removed at radical cystectomy, as a finding of ASAP of the prostate on needle-core biopsy is closely associated with the detection of cancer on subsequent biopsy.
  • The presence of high-grade prostatic intraepithelial neoplasia (HGPIN), ASAP, and adenocarcinoma was recorded.
  • RESULTS: In all, 24 of 65 specimens (37%) had adenocarcinoma.
  • The remaining eight foci all lacked CK903 stain, indicating disruption of the basal cell layer.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Cystectomy / methods. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prostate / pathology. Prostatectomy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378841.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Seretis EC, Gavriil AN, Golematis VC, Voloudakis-Baltatzis IE: Immunoelectron study of pancreatic carcinomas using antibodies to gastrointestinal hormones. Ultrastruct Pathol; 2007 Jul-Aug;31(4):303-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoelectron study of pancreatic carcinomas using antibodies to gastrointestinal hormones.
  • The aim of this study was to investigate the ultrastructural appearance of pancreatic adenocarcinoma combined with glucagon and gastrin/cholecystokinin (CCK) expression.
  • The authors investigated the ultrastructure and the immunocytochemistry of 12 human pancreatic cancer specimens and used 3 chronic pancreatitis samples and 6 adjacent histological normal pancreatic tissues (away from the tumor) as controls.
  • Glucagon appeared to be located not only in islet alpha cells but also in intermediate alpha acinar cells.
  • The changes were more significant in adenocarcinoma cases.
  • Abnormality in the immunoreaction of the peptides was indicated not only in the tumor area but also in the islets near the cancer.
  • Cells immunoreactive with antibodies were found in all 12 adenocarcinoma cases.
  • Abnormal co-location of both hormones in the same type of endocrine cell was also found.
  • Moderately to poorly differentiated adenocarcinomas were poorly granulated compared with differentiated tumors.
  • Increased and ectopic gastrin/CCK expression was correlated with pancreatic adenocarcinomas exhibiting poor histological grade and neoplastic endocrine cells, providing a potential marker for pancreatic adenocarcinomas with aggressive behavior.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / ultrastructure. Antibodies, Monoclonal. Gastrointestinal Hormones / biosynthesis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / ultrastructure

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786831.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Hormones; 9007-92-5 / Glucagon; 9011-97-6 / Cholecystokinin
  •  go-up   go-down


39. Sawey ET, Johnson JA, Crawford HC: Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proc Natl Acad Sci U S A; 2007 Dec 4;104(49):19327-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway.
  • Acinar-to-ductal metaplasia in the pancreas is associated with an increased risk for tumorigenesis.
  • Molecular dissection of this process in vitro has shown that primary acinar cells, in response to EGF receptor ligands, can transdifferentiate into duct-like epithelia, passing through a nestin-positive intermediate, in a Notch pathway-dependent manner.
  • Here, we show that in vitro acinar transdifferentiation depends on matrix metalloproteinase 7 (MMP-7), a proteinase expressed in most metaplastic epithelia in vivo.
  • MMP-7 was found to be required for Notch activation, which leads to dedifferentiation of acinar cells to the nestin-positive transitional cell.
  • Besides being necessary for acinar transdifferentiation, it was found that MMP-7 activity was sufficient to induce the process, indicating that molecular signals capable of initiating MMP-7 expression also have the potential to induce formation of metaplastic epithelia in the pancreas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1416-26 [10579983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1825-35 [10669757.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):12-20 [10962434.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1355-8 [11396212.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(21):2615-24 [12354787.001]
  • [Cites] Cell. 2002 Nov 27;111(5):635-46 [12464176.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1831-43 [12759241.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1235-40 [14977820.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1285-90 [2982487.001]
  • [Cites] Eur J Cell Biol. 1990 Feb;51(1):64-75 [2184038.001]
  • [Cites] Mol Carcinog. 1991;4(6):527-33 [1793490.001]
  • [Cites] Princess Takamatsu Symp. 1994;24:152-61 [8983072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Cell. 1997 Jul 25;90(2):271-80 [9244301.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • [Cites] FEBS Lett. 1998 Sep 11;435(1):39-44 [9755855.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1254-62 [9797382.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5500-6 [9850086.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):117-30 [16354684.001]
  • [Cites] Biochem J. 2006 Feb 1;393(Pt 3):679-85 [16201968.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] J Cell Biol. 2007 Feb 12;176(4):445-58 [17296795.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] J Clin Invest. 2000 Jan;105(2):143-50 [10642592.001]
  • (PMID = 18042722.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100126; United States / NCI NIH HHS / CA / R01CA100126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Notch; EC 3.4.24.23 / Matrix Metalloproteinase 7
  • [Other-IDs] NLM/ PMC2148289
  •  go-up   go-down


40. Arista-Nasr J, Martínez-Benítez B, Fernández-Amador JA, Bornstein-Quevedo L, Albores-Saavedra J: [Pseudohyperplastic carcinoma with xanthomatous changes: a neoplasm mimicking glandular hyperplasia of the prostate]. Actas Urol Esp; 2010 Apr;34(4):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudohyperplastic carcinoma with xanthomatous changes: a neoplasm mimicking glandular hyperplasia of the prostate].
  • [Transliterated title] Carcinoma pseudohiperplásico con cambios xantomatosos: una neoplasia que semeja hiperplasia glandular de la próstata.
  • INTRODUCTION AND OBJECTIVES: Varieties of prostatic adenocarcinoma whose architectural and cytological appearance mimicked benign lesions have been reported in recent decades.
  • Such neoplasms include xanthomatous (foamy) carcinoma and pseudohyperplastic carcinoma.
  • We recently studied five carcinomas showing a cytoarchitectural combination of both neoplasms which were confused with benign glandular proliferations.
  • METHODS: Five cases (1.8%) of pseudohyperplastic carcinoma showing xanthomatous changes were selected from a total of 280 biopsies showing prostate carcinoma.
  • Several useful criteria for diagnosis of acinar carcinoma, such as perineural infiltration, mitosis, crystalloids, blue secretions, and prostatic intraepithelial neoplasm, were absent.
  • CONCLUSIONS: Prostatic carcinoma with a pseudohyperplastic pattern and xanthomatous changes mimics hyperplastic glands.
  • [MeSH-major] Carcinoma / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Xanthomatosis / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20470695.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Shi G, Zhu L, Sun Y, Bettencourt R, Damsz B, Hruban RH, Konieczny SF: Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology; 2009 Apr;136(4):1368-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia.
  • BACKGROUND & AIMS: Invasive pancreatic ductal adenocarcinoma is thought to originate from duct-like lesions called pancreatic intraepithelial neoplasia (PanIN).
  • METHODS: In this study, we examined the importance of the acinar-restricted transcription factor Mist1 to KrasG12D-induced mouse PanIN (mPanIN) formation in 3 different mouse models of pancreatic cancer.
  • RESULTS: In the absence of Mist1 (Mist1KO), KrasG12D-expressing mice exhibited severe exocrine pancreatic defects that were rescued by ectopic expression of Mist1 in acinar cells. mPanIN development was greatly accelerated in Mist1KO/KrasG12D/+ pancreata, and in vitro assays revealed that Mist1KO acinar cells were predisposed to convert to a ductal phenotype and activate epidermal growth factor receptor (EGFR) and Notch-signaling pathways.
  • CONCLUSIONS: We propose that convergence of EGFR, Notch, and Kras pathways in acinar cells lacking Mist1 leads to enhanced mPanIN formation.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anat Rec. 2000 Jun 1;259(2):157-67 [10820318.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):286-93 [11159909.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):519-30 [11696558.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3315-25 [12829745.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mech Dev. 2004 Mar;121(3):261-72 [15003629.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2673-81 [15024058.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1121-35 [1693546.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 28;237(3):752-7 [9299439.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):81-91 [15731576.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12668-75 [15665001.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1123-32 [17170023.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] Gastroenterology. 2008 Nov;135(5):1687-97 [18762186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18907-12 [19028876.001]
  • (PMID = 19249398.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK055489-10; United States / NCI NIH HHS / CA / P50CA62924; United States / NCI NIH HHS / CA / R01 CA124586-02; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIDDK NIH HHS / DK / DK055489-10; United States / NCI NIH HHS / CA / CA124586-02; United States / NIDDK NIH HHS / DK / DK55489; United States / NIDDK NIH HHS / DK / R01 DK055489; United States / NCI NIH HHS / CA / R01 CA124586; United States / NCI NIH HHS / CA / CA124586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Mist1 protein, mouse; 0 / Receptors, Notch; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ NIHMS182460; NLM/ PMC2845927
  •  go-up   go-down


42. Chan WH, Lee KW, Chiang FY, Ho KY, Chai CY, Kuo WR: Features of parotid gland diseases and surgical results in southern Taiwan. Kaohsiung J Med Sci; 2010 Sep;26(9):483-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various parotid gland diseases are seen clinically, including inflammation, sialolithiasis, and benign and malignant tumors.
  • It is important to differentiate between these to make a correct diagnosis and for proper management.
  • Here, we investigated the relationship between tumor characteristics and pathology, and considered whether the former could be used to differentiate malignant from benign parotid gland diseases.
  • Two hundred and eighty-one patients (88.9%) had benign disease, and 35 (11.1%) had malignant disease.
  • The most common benign disease was pleomorphic adenoma (115 cases, 36.4%), but the most common disease in male patients was Warthin's tumor, a finding which, as far as we aware, has not been previously been reported in the literature.
  • The incidence of Warthin's tumor seems to be increasing.
  • In malignant disease, the most common was acinic cell carcinoma (8 cases, 22.9%).
  • Compared with benign disease, malignant parotid gland disease more often presents as a hard, painful, fixed and large mass (> 3 cm), and more often involves the deep lobe of the parotid gland.
  • Partial parotidectomy was adequate for most tumors, including pleomorphic adenoma.
  • However, there was no difference in transient facial palsy rate between benign and malignant parotid gland disease, although parotid gland cancer had a higher incidence of permanent facial palsy postoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Kaohsiung J Med Sci. 2012 Jun;28(6):350-1 [22632893.001]
  • (PMID = 20837345.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


43. Nagler RM, Ben-Izhak O, Ostrovsky D, Golz A, Hershko DD: The expression and prognostic significance of Cks1 in salivary cancer. Cancer Invest; 2009 Jun;27(5):512-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. CDC2-CDC28 Kinases. Carcinoma, Acinar Cell / enzymology. Carcinoma, Acinar Cell / secondary. Carcinoma, Mucoepidermoid / enzymology. Carcinoma, Mucoepidermoid / secondary. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / secondary. Female. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Proliferating Cell Nuclear Antigen / metabolism. S-Phase Kinase-Associated Proteins / metabolism. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296297.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKS1B protein, human; 0 / Carrier Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / S-Phase Kinase-Associated Proteins; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


44. Patel J, Layfield LJ: Histopathologic review of previously negative prostatic core needle biopsies following a new diagnosis of adenocarcinoma of the prostate by core needle biopsies: implications for quality assurance programs. Clin Med Pathol; 2008;1:77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic review of previously negative prostatic core needle biopsies following a new diagnosis of adenocarcinoma of the prostate by core needle biopsies: implications for quality assurance programs.
  • Cytopathologists have instituted QA procedures including review of all previously negative slides received within five years prior to the new diagnosis of high grade squamous intraepithelial lesion or gynecologic malignancy.
  • No such requirement exists in surgical pathology for review of core biopsies.The Department of Pathology at the University of Utah instituted a QA policy requiring review of prior negative prostatic needle biopsies following a new diagnosis of prostatic adenocarcinoma.
  • Two hundred and ninety-five of these contained at least one biopsy with a diagnosis of adenocarcinoma.
  • Two hundred and eight patients had a prior set of prostatic needle biopsies with a diagnosis of adenocarcinoma.
  • The remaining 87 had prior biopsies with either a diagnosis of prostatic intraepithelial neoplasia (23), small atypical acinar proliferation (21) or no evidence of malignancy (43).
  • QA review of these 87 cases revealed two biopsies which revealed foci of adenocarcinoma.
  • In an additional twenty-one cases, microscopic foci of atypical small acinar proliferations were found in core biopsies antedating the positive core biopsy (7.1%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1999 Aug;94(2):302-6 [10432147.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):280-4 [10680896.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):801-5 [15897747.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • [Cites] Int J Gynecol Pathol. 1998 Jan;17(1):36-41 [9475190.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Int J Gynecol Pathol. 1998 Jan;17(1):42-5 [9475191.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] Am J Clin Pathol. 1995 Nov;104(5):560-6 [7572817.001]
  • (PMID = 21876655.001).
  • [ISSN] 1178-1181
  • [Journal-full-title] Clinical medicine. Pathology
  • [ISO-abbreviation] Clin Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3159997
  • [Keywords] NOTNLM ; core needle biopsy / diagnostic errors / prostate / quality assurance
  •  go-up   go-down


45. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • The purpose of this study was to evaluate the expression of topoIIalpha in various types of salivary gland tumors and its biological significance.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


46. Kim KA, Kim MJ, Jang SJ: A pancreatic mass presented with multiple hot spots in the subcutaneous fat layer on positron emission tomography. Acinar cell carcinoma with multiple fat necrosis. Gastroenterology; 2010 Oct;139(4):e10-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pancreatic mass presented with multiple hot spots in the subcutaneous fat layer on positron emission tomography. Acinar cell carcinoma with multiple fat necrosis.
  • [MeSH-major] Carcinoma, Acinar Cell / radionuclide imaging. Fluorodeoxyglucose F18. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Subcutaneous Fat / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20800656.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Kaifi JT, Heidtmann S, Schurr PG, Reichelt U, Mann O, Yekebas EF, Wachowiak R, Strate T, Schachner M, Izbicki JR: Absence of L1 in pancreatic masses distinguishes adenocarcinomas from poorly differentiated neuroendocrine carcinomas. Anticancer Res; 2006 Mar-Apr;26(2A):1167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of L1 in pancreatic masses distinguishes adenocarcinomas from poorly differentiated neuroendocrine carcinomas.
  • BACKGROUND: Pancreatic adenocarcinoma is a tumor with fatal outcome.
  • Cell adhesion molecules, such as L1 (CD171), have an essential function in tumor progression.
  • L1 has been shown to be specifically expressed in poorly differentiated neuroendocrine carcinomas of the pancreas.
  • The aim of this study was to determine the expression of L1 in pancreatic adenocarcinomas to evaluate whether L1 might differentiate between pancreatic carcinomas of neuroendocrine and ductal origin.
  • MATERIALS AND METHODS: L1 expression was retrospectively analyzed in 111 cases of pancreatic adenocarcinomas by immunohistochemistry on paraffin sections of primary tumors.
  • All tumors were classified according to the most recent TNM classification.
  • RESULTS: The focal expression of L1 was detected in 2 (2%) out of 111 pancreatic carcinomas only, the remaining 109 (98%) being L1-negative.
  • No expression was found in acinar or ductal cells of normal pancreatic tissue.
  • CONCLUSION: Our data suggest that L1 is expressed in few cases of pancreatic ductal adenocarcinoma.
  • Since L1 was previously found to be expressed specifically in neuroendocrine pancreatic carcinomas, its absence in unclear pancreatic masses might hint at a ductal origin for a malignant pancreatic tumor.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / immunology. Carcinoma, Neuroendocrine / pathology. Leukocyte L1 Antigen Complex / biosynthesis. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619519.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


48. Igarashi H, Shinozaki S, Mukada T: A case of acinar cell carcinoma of the pancreas that formed extensive tumor thrombus of the portal vein. Clin J Gastroenterol; 2009 Apr;2(2):96-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of acinar cell carcinoma of the pancreas that formed extensive tumor thrombus of the portal vein.
  • Furthermore, tumor thrombus continuously involved the splenic and proximal superior mesenteric vein, main portal vein, and its right intrahepatic branch.
  • The specimens obtained from portal tumor thrombus were histologically compatible with acinar cell carcinoma.
  • Portal tumor thrombus is a rare condition in pancreatic tumors; however, it seems to be important to differentiate tumor thrombus from blood thrombus of the portal vein in order to know the true clinical stage and provide a suitable treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 1995 Aug;30(4):529-33 [7550867.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):1000-5 [8884328.001]
  • [Cites] Eur Radiol. 2001;11(9):1642-4 [11511884.001]
  • [Cites] Ultraschall Med. 2007 Feb;28(1):75-8 [17304414.001]
  • [Cites] Am J Gastroenterol. 1996 Jun;91(6):1268-9 [8651190.001]
  • [Cites] Surg Today. 2004;34(9):802-4 [15338361.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):887-9 [10919054.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):291-3 [15043751.001]
  • [Cites] J Assoc Physicians India. 1999 Jul;47(7):730-2 [10778598.001]
  • [Cites] Abdom Imaging. 2006 Mar-Apr;31(2):245-8 [16283584.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(3):256-9 [16708305.001]
  • [Cites] J Pediatr Surg. 2006 Mar;41(3):596-8 [16516645.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1585-8 [17708306.001]
  • [Cites] World J Surg. 2003 Mar;27(3):299-303 [12607055.001]
  • [Cites] J Comput Assist Tomogr. 1998 Mar-Apr;22(2):335-9 [9530406.001]
  • [Cites] Abdom Imaging. 2004 Jul-Aug;29(4):460-2 [15024520.001]
  • [Cites] N Engl J Med. 1968 Dec 5;279(23):1279-85 [4880017.001]
  • [Cites] Radiology. 1975 Nov;117(2):303-9 [170642.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):364-5 [16105519.001]
  • [Cites] Magn Reson Imaging. 1999 Sep;17(7):1093-6 [10463662.001]
  • [Cites] J Gastroenterol. 2002;37(3):220-8 [11931537.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):811-4 [1689502.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):239-40 [11818930.001]
  • [Cites] Pancreas. 2003 Aug;27(2):201-3 [12883272.001]
  • [Cites] Surg Today. 1996;26(5):357-60 [8726623.001]
  • [Cites] Int J Hematol. 2006 Oct;84(3):282-3 [17050206.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1631-3 [14571802.001]
  • [Cites] Radiat Med. 1989 Mar-Apr;7(2):66-73 [2552504.001]
  • [Cites] Surg Today. 1992;22(1):62-5 [1312375.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Jun;19(6):519-20 [17489064.001]
  • [Cites] Gastroenterol Jpn. 1989 Aug;24(4):414-20 [2777018.001]
  • [Cites] AJR Am J Roentgenol. 1981 May;136(5):897-900 [6784524.001]
  • [Cites] Surg Today. 1998;28(10 ):1046-50 [9786577.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1693-6 [14571819.001]
  • [Cites] Gut. 1991 May;32(5):542-5 [1710199.001]
  • [Cites] Intern Med. 2007;46(6):273-7 [17379993.001]
  • (PMID = 26192173.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Acinar cell carcinoma / Pancreas / Portal vein / Tumor thrombus
  •  go-up   go-down


49. Mazzullo G, Sfacteria A, Ianelli N, De Majo M, Pennisi MG: Carcinoma of the submandibular salivary glands with multiple metastases in a cat. Vet Clin Pathol; 2005;34(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the submandibular salivary glands with multiple metastases in a cat.
  • Slides were stained with May-Grünwald Giemsa, and a diagnosis of salivary gland carcinoma was made.
  • At surgery, the tumor was found to involve both submandibular salivary glands as well as adjacent lymph nodes and surrounding tissues.
  • The majority of tissues and organs examined histologically, including mandibular and retropharyngeal lymph nodes, soft palate, laryngopharynx and lungs, contained neoplastic cells whose appearance was consistent with adenocarcinoma.
  • Bilateral salivary adenocarcinoma has not previously been reported in cats, and extensive metastases are rare.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732021.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Reske SN: [PET and PET-CT of malignant tumors of the exocrine pancreas]. Radiologe; 2009 Feb;49(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PET and PET-CT of malignant tumors of the exocrine pancreas].
  • Adenocarcinomas of the pancreas represent the majority (>95%) of all malignant pancreatic tumors.
  • They are formed from malignant degeneration of the exocrine part of the pancreas.
  • Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas.
  • Endocrine tumors of the pancreas will not be dealt with in this context.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoma, Acinar Cell / diagnostic imaging. Carcinoma, Pancreatic Ductal / diagnostic imaging. Image Processing, Computer-Assisted. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis / diagnostic imaging. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Staging. Pancreas / diagnostic imaging. Pancreas / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1437-44 [18703612.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Eur J Nucl Med. 1998 Mar;25(3):259-64 [9580859.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):250-5 [10025831.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1352 [15197505.001]
  • [Cites] J Gastroenterol. 2003;38(12 ):1189-93 [14714260.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):399-404 [15549297.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):475-6 [16012303.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Gastroenterol Clin Biol. 2002 Oct;26(10 ):888-92 [12434099.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85 [18481063.001]
  • [Cites] Recent Results Cancer Res. 2008;177:15-26 [18084943.001]
  • [Cites] Nuklearmedizin. 2005;44 Suppl 1:S18-23 [16395974.001]
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):197-201 [11852308.001]
  • [Cites] Scand J Surg. 2004;93(3):191-7 [15544073.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):131-136 [14516536.001]
  • [Cites] J Nucl Med. 2008 Sep;49(9):1408-13 [18703604.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10 (10 ):1354-60 [17175454.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):50-5 [14767734.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):287-93 [10917540.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Ann Nucl Med. 2001 Jun;15(3):217-24 [11545191.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Pancreas. 2000 Mar;20(2):109-16 [10707924.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Pancreatology. 2005;5(6):553-61 [16113592.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):239-46 [15972430.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):480-508 [18287273.001]
  • [Cites] Pancreatology. 2005;5(2-3):266-72 [15855825.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19219476.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 43
  •  go-up   go-down


51. Vargas PA, Torres-Rendon A, Speight PM: DNA ploidy analysis in salivary gland tumours by image cytometry. J Oral Pathol Med; 2007 Jul;36(6):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine whether DNA ploidy by image cytometry is a good diagnostic tool to distinguish benign and malignant salivary gland tumours.
  • According to the World Health Organization (WHO) classification, there were 14 mucoepidermoid carcinomas (MEC), 11 adenoid cystic carcinomas (ACC), 10 pleomorphic adenomas (PA), 10 carcinoma ex PA (CEPA), 9 acinic cell carcinomas (ACCa), 3 polymorphous low-grade adenocarcinomas (PLGA), 2 papillary cystadenocarcinomas (PC), 1 myoepithelial carcinoma (MC), 1 undifferentiated carcinoma (UC) and 1 mucinous adenocarcinoma (MA).
  • Paraffin sections (40 microm) were micro-dissected to isolate tumour areas; cell nuclei were extracted and Feulgen-stained cytospin monolayers were analysed using a DNA image cytometry system.
  • High-grade malignancies may be aneuploid, and ploidy may be useful to identify malignant change in atypical PA.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559500.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


52. Tarasova MV, Pozharisskiĭ KM, Ten VP, Arzumanov AA, Kudaĭbergenova AG: [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma]. Arkh Patol; 2009 Nov-Dec;71(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma].
  • The authors have made an immunohistochemical determination of Ki-67, topoisomerase IIalpha, cyclins D1, A, and B1, and calculated their indices in 145 acinar adenocarcinomas of the prostate.
  • This tumor is characterized by a wide range of Ki-67 index (from 3 to 90% or more) although 90% of cases are in the range of 5-35%.
  • The exception is cyclin D1 that shows high expression in intact and tumor tissues, which is frequently greater than that of Ki-67, and its stable expression independent of the Gleason score.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131501.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


53. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R: Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer. Acta Otolaryngol; 2008 Apr;128(4):482-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: In the current study matrix metalloproteinases (MMPs)-9 and -13 were associated with the prognosis in salivary gland cancer (SGC), indicating that they contribute to the progression and invasion of these malignant tumours.
  • High MMP-13 intensity (2+3 vs 1; p=0.05), percentage (2 vs 1; p=0.03) and index (3 vs 1; p=0.02) were associated with poor survival in acinic cell carcinoma.
  • However, high MMP-9 index in adenoid cystic carcinoma (p=0.06) and the percentage of positively staining cells in salivary duct carcinoma patients (p=0.05) was associated with poor survival.
  • [MeSH-major] Carcinoma / enzymology. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 13 / metabolism. Matrix Metalloproteinase 9 / metabolism. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Finland / epidemiology. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate / trends. Time Factors

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368586.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.- / Matrix Metalloproteinase 13; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


54. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, Konieczny SF, Leach SD, Maitra A: Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A; 2008 Dec 2;105(48):18913-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice.
  • Pancreatic ductal adenocarcinoma (PDAC) is believed to arise through a multistep model comprised of putative precursor lesions known as pancreatic intraepithelial neoplasia (PanIN).
  • Recent genetically engineered mouse models of PDAC demonstrate a comparable morphologic spectrum of murine PanIN (mPanIN) lesions.
  • The most faithful genetic models activate an oncogenic Kras(G12D) knockin allele within the pdx1- or ptf1a/p48-expression domain of the entire pancreatic anlage during development, thus obscuring the putative cell(s)-of-origin from which subsequent mPanIN lesions arise.
  • In our study, activation of this knockin Kras(G12D) allele in the Elastase- and Mist1-expressing mature acinar compartment of adult mice resulted in the spontaneous induction of mPanIN lesions of all histological grades, although invasive carcinomas per se were not seen.
  • We observed no requirement for concomitant chronic exocrine injury in the induction of mPanIN lesions from the mature acinar cell compartment.
  • The acinar cell derivation of the mPanINs was established through lineage tracing in reporter mice, and by microdissection of lesional tissue demonstrating Cre-mediated recombination events.
  • We conclude that in the appropriate genetic context, the differentiated acinar cell compartment in adult mice retains its susceptibility for spontaneous transformation into mPanIN lesions, a finding with potential relevance vis-à-vis the origins of PDAC.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6N.129S6-Bhlha15<tm2(Kras)Skz>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):853-9 [12808120.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:71-89 [14570564.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:13 [12636873.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] J Surg Oncol. 1975;7(2):139-41 [1097831.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Nature. 1984 Nov 1-7;312(5989):71-5 [6092966.001]
  • [Cites] Yale J Biol Med. 1992 Sep-Oct;65(5):457-64; discussion 465-9 [1340063.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):77-87 [10360219.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S78-82 [15758664.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):728-41 [15765408.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cell Cycle. 2006 Jan;5(1):43-6 [16322695.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3161-73 [17114586.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):451-3 [17157783.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4419-24 [17360539.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1999-2009 [18054571.001]
  • [Cites] Cell. 2008 Jan 25;132(2):197-207 [18243096.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):621-31 [18515092.001]
  • (PMID = 19028870.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK56211; United States / NIDDK NIH HHS / DK / R21 DK072532-01; United States / NCI NIH HHS / CA / R01 CA113669-02; United States / NIDDK NIH HHS / DK / R21 DK072532-02; United States / NCI NIH HHS / CA / R01 CA113669-01; United States / NCI NIH HHS / CA / CA113669-02; United States / NCI NIH HHS / CA / CA113669-04; United States / NIDDK NIH HHS / DK / DK072532-01; United States / NCI NIH HHS / CA / CA113669-03; United States / NCI NIH HHS / CA / CA113669; United States / NIDDK NIH HHS / DK / DK55489; United States / NIDDK NIH HHS / DK / DK072532; United States / NIDDK NIH HHS / DK / R01 DK055489-11A1; United States / NIDDK NIH HHS / DK / R01 DK055489; United States / NCI NIH HHS / CA / R01 CA124586-04; United States / NCI NIH HHS / CA / R01 CA113669-05; United States / NIDDK NIH HHS / DK / DK61215; United States / NIDDK NIH HHS / DK / R21 DK072532; United States / NIDDK NIH HHS / DK / R01 DK061215; United States / NCI NIH HHS / CA / R01 CA113669-03; United States / NCI NIH HHS / CA / CA124586-04; United States / NIDDK NIH HHS / DK / T32 DK007713; United States / NCI NIH HHS / CA / R01 CA124586; United States / NIDDK NIH HHS / DK / T32DK007713; United States / NCI NIH HHS / CA / CA124586; United States / NIDDK NIH HHS / DK / DK055489-11A1; United States / NCI NIH HHS / CA / R01 CA113669; United States / NIDDK NIH HHS / DK / R01 DK056211; United States / NCI NIH HHS / CA / R01 CA113669-04; United States / NCI NIH HHS / CA / CA113669-05; United States / NIDDK NIH HHS / DK / DK072532-02; United States / NCI NIH HHS / CA / CA113669-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2596215
  •  go-up   go-down


55. Marrache F, Tu SP, Bhagat G, Pendyala S, Osterreicher CH, Gordon S, Ramanathan V, Penz-Osterreicher M, Betz KS, Song Z, Wang TC: Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology; 2008 Oct;135(4):1277-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Chronic pancreatitis is a significant cause of morbidity and a known risk factor for pancreatic adenocarcinoma.
  • There was evidence for increased acinar proliferation and apoptosis, along with prominent expression of tumor necrosis factor-alpha; chemokine (C-X-C motif) ligand 1; stromal cell-derived factor 1; transforming growth factor-beta1; matrix metallopeptidase 2, 7, and 9; inhibitor of metalloproteinase 1; and cyclooxygenase 2.
  • Older mice displayed acinar-ductal metaplasia but did not develop mouse pancreatic intraepithelial neoplasia or tumors.
  • Elastase sshIL-1beta*p53(R172H/+) mice had increased frequency of tubular complexes, some of which were acinar-ductal metaplasia.
  • Elastase sshIL-1beta mice consistently develop severe chronic pancreatitis and constitute a promising model for studying chronic pancreatitis and its relationship with pancreatic adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Development. 2005 Aug;132(16):3767-76 [16020518.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:65-72 [16869739.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3147-60 [17114585.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1856-69 [17123526.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1557-73 [17466744.001]
  • [Cites] Dig Dis. 2007;25(3):282-4 [17827958.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):582-90 [10702210.001]
  • [Cites] Dig Dis Sci. 2000 Apr;45(4):665-74 [10759232.001]
  • [Cites] Diabetes. 2001 Jul;50(7):1553-61 [11423476.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1153-63 [11430819.001]
  • [Cites] JAMA. 2001 Jul 11;286(2):169-70 [11448279.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1105-12 [12016137.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):877-88 [12975454.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1481-93 [15039235.001]
  • [Cites] J Clin Invest. 2004 May;113(10):1398-407 [15146237.001]
  • [Cites] Am Rev Respir Dis. 1987 Jan;135(1):66-71 [2948432.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Arch Histol Cytol. 1995 Aug;58(3):365-74 [8527243.001]
  • [Cites] Cell Immunol. 1996 May 1;169(2):226-37 [8620550.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):231-6 [8661203.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1656-63 [9136845.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1664-72 [9136846.001]
  • [Cites] EMBO J. 1997 May 15;16(10):2621-33 [9184209.001]
  • [Cites] Immunology. 1999 Jan;96(1):128-37 [10233687.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1587-95 [10359568.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Apr;32(4):311-8 [15668323.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • (PMID = 18789941.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093405; United States / NCI NIH HHS / CA / R01 CA120979-03; United States / NCI NIH HHS / CA / U54 CA126513; United States / NCI NIH HHS / CA / R01 CA093405-07A1; United States / NCI NIH HHS / CA / CA093405-07A1; United States / NCI NIH HHS / CA / CA120979-03; United States / NCI NIH HHS / CA / U54 CA126513-03; United States / NCI NIH HHS / CA / CA126513-03; United States / NCI NIH HHS / CA / R01 CA120979
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta; EC 3.4.21.36 / Pancreatic Elastase
  • [Other-IDs] NLM/ NIHMS73579; NLM/ PMC2707078
  •  go-up   go-down


56. Spencer ML, Neto AG, Fuller GN, Luna MA: Intracranial extension of acinic cell carcinoma of the parotid gland. Arch Pathol Lab Med; 2005 Jun;129(6):780-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial extension of acinic cell carcinoma of the parotid gland.
  • We report the case of a 47-year-old woman who experienced multiple recurrences of acinic cell carcinoma, lung metastasis, and intracranial extension of the tumor during a 32-year period.
  • In this report, the clinical, microscopic, histochemical, and electron microscopy features of this acinic cell carcinoma are described, and a review of published information about this neoplasm is presented.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Acinar Cell / secondary. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913428.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Cakir E, Demirag F, Aydin M, Unsal E: Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol; 2009 Jan;37(1):4-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
  • Distinguishing malignant mesothelioma, adenocarcinoma and reactive mesothelial proliferation in both cytologic and surgical pathologic specimens is often a diagnostic challenge.
  • Conventional cytomorphologic assessment is an important step in the differential diagnosis of these entities.The pleural effusion cytologies from 40 cases of malignant mesothelioma, 40 cases of adenocarcinoma and 30 cases of reactive mesothelial proliferation diagnosed between 1997 and 2007 were reviewed.
  • Twenty-seven cytologic features which are regarded as useful in the differential diagnosis of mesothelioma, adenocarcinoma and benign mesothelial proliferation were assessed.
  • Three features were selected to distinguish malignant mesothelioma from adenocarcinoma: giant atypical mesothelial cell (P = 0.0001), nuclear pleomorphism (P = 0.0001) and acinar structures (P = 0.0001), the latter two being characteristics of adenocarcinoma.
  • The variables selected to differentiate malignant mesothelioma from reactive mesothelial cells were: cell ball formation (P = 0.0001), cell in cell engulfment (P = 0.0001) and monolayer cell groups (P = 0.0001), the latter being a feature of benign mesothelial proliferation.
  • When these selected variables were subjected to a stepwise logistic regression analysis, the logistic model correctly predicted 90% of cases of benign mesothelial proliferation versus 97.5% of malignant mesothelioma and 92.5% of malignant mesothelioma versus 92.5% of adenocarcinoma.Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in pleural effusions.
  • Several cytologic features have predictive value to separate malignant mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Mesothelioma / diagnosis. Neoplasms, Mesothelial / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Logistic Models

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973123.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Kawakami T, Nabeshima K, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H: Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch; 2009 Jan;454(1):61-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas.
  • Lung adenocarcinomas with micropapillary pattern (MPP) are associated with frequent nodal metastasis.
  • In this study, we investigated how small micropapillary clusters of carcinoma cells present in tumoral alveolar spaces lead to increased lymph node metastasis.
  • We analyzed 146 cases of pT1 lung adenocarcinomas with reference to the presence of MPP, small cluster invasion (SCI), and lymphatic involvement.
  • SCI was defined as markedly resolved acinar-papillary tumor structures with single or small clusters of carcinoma cells invading stroma within fibrotic foci.
  • Carcinoma cells undergoing SCI demonstrated the same characteristic MUC-1 expression on the outer surface of cell clusters as those undergoing MPP.
  • Thus, SCI could link MPP to nodal metastasis; carcinoma cells with MPP tend to undergo SCI in scars and invade lymphatics in pT1 lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Pulmonary Alveoli / pathology. Respiratory Mucosa / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1960 Sep;16:296-308 [13717558.001]
  • [Cites] Dis Colon Rectum. 1993 Jul;36(7):627-35 [8348847.001]
  • [Cites] Virchows Arch. 2000 Oct;437(4):465-8 [11097376.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] Histopathology. 2005 Nov;47(5):479-84 [16241995.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]
  • [Cites] Histopathology. 2005 Jun;46(6):677-84 [15910599.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):515-23 [10027409.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):992-1001 [18516041.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]
  • [Cites] Mod Pathol. 2007 May;20(5):514-21 [17334347.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):729-33 [17464318.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):809-15 [16784979.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):836-41 [11557778.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1113-21 [11021815.001]
  • [Cites] Pathol Int. 2000 Jan;50(1):52-6 [10692178.001]
  • [Cites] Arch Pathol Lab Med. 2000 Sep;124(9):1347-8 [10975935.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):81-6 [15098251.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2976-87 [16707592.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1045-50 [15154007.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):43-51 [8990140.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):324-30 [18261622.001]
  • [Cites] Histopathology. 2004 Dec;45(6):580-6 [15569048.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 24):4491-500 [10574699.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):431-8 [8172319.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):857-66 [15198358.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):638-47 [17431413.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1183-97 [10506935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):419-24 [15982217.001]
  • (PMID = 19002492.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Seth AK, Argani P, Campbell KA, Cameron JL, Pawlik TM, Schulick RD, Choti MA, Wolfgang CL: Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg; 2008 Jun;12(6):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature.
  • INTRODUCTION: Acinar cell carcinoma (ACC) is a rare, malignant neoplasm with a generally poor prognosis.
  • MATERIALS AND METHODS: The Johns Hopkins pathology prospective database was reviewed from 1988 to 2006 to identify patients with pancreatic neoplasms possessing features of acinar cell differentiation.
  • Median tumor size was 3.9 cm with 12 patients found to have stage IIB disease or worse.
  • Eight of the fourteen patients developed recurrent disease.
  • Overall median survival and disease-free survival were 33 and 25 months, respectively, as compared to a median survival of 18 months for pancreatic adenocarcinoma.
  • CONCLUSION: Acinar cell carcinomas are rare, aggressive neoplasms that are difficult to diagnose and treat.
  • These lesions have a better prognosis than the more common pancreatic adenocarcinomas.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 1994 Jan;9(1):53-8 [8003821.001]
  • [Cites] Pancreas. 2001 Apr;22(3):326-9 [11291937.001]
  • [Cites] Can Med Assoc J. 1962 Nov 3;87:970-3 [14011794.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Br Med J. 1970 Jun 20;2(5711):708-9 [5429656.001]
  • [Cites] Mayo Clin Proc. 1979 Jul;54(7):449-58 [221755.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Int Surg. 1984 Oct-Dec;69(4):361-4 [6084650.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):180-6 [15091120.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):67-72 [15361637.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1568-71 [15619219.001]
  • [Cites] Gut. 1990 Aug;31(8):953-5 [2387523.001]
  • [Cites] Ultrastruct Pathol. 2000 Jul-Aug;24(4):227-41 [11013963.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Clin Pathol. 1977 Feb;30(2):103-12 [845259.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):85-93 [3812876.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):222-5 [10982618.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):772-7 [11072247.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):397-402 [4005804.001]
  • [Cites] Cancer. 1974 Apr;33(4):1002-9 [4819206.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Gastroenterology. 1965 Nov;49(5):555-9 [5853162.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):191-7 [16442944.001]
  • (PMID = 17957440.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Omlie JE, Koutlas IG: Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases. J Oral Maxillofac Surg; 2010 Sep;68(9):2053-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases.
  • PURPOSE: Acinic cell carcinoma (ACC) is an infrequent type of malignant salivary gland tumor.
  • This study was undertaken to 1) report on the clinicopathologic characteristics of 21 intraoral examples, 2) reconfirm the reported indolent behavior of these tumors, and 3) verify the synchronous or metachronous occurrence of other malignancies with ACC.
  • The size of the tumors varied from 0.6 to 1.6 cm.
  • Eleven patients did not report recurrence or metastatic disease.
  • One patient had 2 recurrences due to erroneous diagnosis that led to inappropriate treatment.
  • After properly diagnosed and treated, this patient has been free of tumor for 4 years.
  • Of interest were the metachronous occurrence of lymphoma in 1 patient and the synchronous occurrence of renal cell carcinoma in another.
  • CONCLUSION: This study confirms the indolent behavior of ACC of minor salivary glands and previous reports on the occasional synchronous or metachronous association of malignant salivary gland tumors with other malignancies.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Neoplasms, Multiple Primary. Neoplasms, Second Primary. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Renal Cell / parasitology. Female. Humans. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20576339.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, Miyata Y, Iseki M, Shimizu Y, Tokumoto N, Ozaki S, Asahara T: Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer; 2006;6:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
  • However, often, the discriminating diagnosis of primary lung acinar adenocarcinoma and lung metastasis of colorectal cancer based on morphological and pathological findings is difficult.
  • The purpose of this study was to evaluate the clinical usefulness of immunohistochemistry of beta-catenin, cytokeratin (CK) 7, and CK20 for the discriminating diagnosis of lung cancer.
  • METHODS: We performed immunohistochemistry of beta-catenin, CK7, and CK20 in 19 lung metastasis of colorectal cancer samples, 10 corresponding primary colorectal cancer samples and 11 primary lung acinar adenocarcinoma samples and compared the levels of accuracy of the discriminating diagnosis by using antibodies against these antigens.
  • RESULTS: Positive staining of beta-catenin was observed in all the lung metastasis of colorectal cancer samples as well as in the primary colorectal cancer samples but in none of the primary lung acinar adenocarcinoma samples.
  • Positive staining of CK7 was observed in 90.9% of the primary lung acinar adenocarcinoma samples and in 5.3% of the lung metastasis of colorectal cancer samples, but in none of the primary colorectal cancer samples.
  • Positive staining of CK20 was observed in all the primary colorectal cancer samples and in 84.2% of the lung metastasis of colorectal cancer samples, but in none of the primary lung acinar adenocarcinoma samples.
  • CONCLUSION: Combined immunohistochemistry of beta-catenin, CK7, and CK20 is useful for making a discriminating diagnosis between lung metastasis of colorectal cancer and primary lung acinar adenocarcinoma.
  • This method will enable accurate diagnosis of a lung tumor and will be useful for selecting appropriate therapeutic strategies, including chemotherapeutic agents and operation methods.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Gene Expression Profiling. Humans. Immunohistochemistry. Keratin-20. Keratin-7. Keratins / analysis. Retrospective Studies. Sensitivity and Specificity. beta Catenin / analysis


62. Thomason T, Oxford LE, Ducic Y: Metastatic acinic cell carcinoma presenting as a recurrent pituitary adenoma. J Otolaryngol; 2007 Dec;36(6):E91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic acinic cell carcinoma presenting as a recurrent pituitary adenoma.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076836.001).
  • [ISSN] 0707-7270
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


63. Cheng L, Xu JW, Teng XD: [Histologic variants of prostate cancer]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinosarcoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Small Cell / pathology. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781207.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Striebel JM, Dacic S, Yousem SA: Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol; 2008 Mar;32(3):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma.
  • A total of 211 cases of primary lung adenocarcinoma were tested for expression of gross cystic disease fluid protein-15 (GCDFP-15) and only 11 cases (5.2%) were positive.
  • The cases occurred with an equal sex distribution in older individuals whose carcinomas were frequently identified on screening radiographs.
  • The adenocarcinomas were peripheral lesions and had an average size of 2.9 cm (range, 1.1 to 7.0).
  • Histologically, they were usually mixed acinar and papillary adenocarcinomas with abundant extracellular mucin production, with the neoplastic cells having a polygonal shape, round to oval nuclei, diffuse powdery chromatin, and abundant eosinophilic granular cytoplasm.
  • This report details the first 11 cases of pulmonary adenocarcinoma to express GCDFP-15 and their distinctive morphology with frequent mucin production and coexpression of thyroid transcription factor-1 and synaptophysin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Carrier Proteins / analysis. Glycoproteins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / chemistry. Adenocarcinoma, Papillary / pathology. Aged. Female. Histocytochemistry. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucins / analysis. Nuclear Proteins / analysis. Synaptophysin / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mucins; 0 / Nuclear Proteins; 0 / PIP protein, human; 0 / Synaptophysin; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


65. Layfield LJ, Jarboe EA: Cytopathology of the pancreas: neoplastic and nonneoplastic entities. Ann Diagn Pathol; 2010 Apr;14(2):140-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpretation of cytologic material obtained from the pancreas is complex because of the large number of reactive processes and benign and malignant neoplasms arising within the pancreas.
  • Whereas separation of neuroendocrine, acinar, and ductal neoplasms is usually straightforward, the greatest diagnostic challenge in pancreatic fine-needle aspiration is the separation of atypical epithelium secondary to chronic pancreatitis from well-differentiated ductal adenocarcinoma.
  • Recently, a number of in situ lesions have been identified, complicating the cytologic diagnosis of pancreatic neoplasia.

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227021.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


66. Cheuk DK, Shek TW, Chan GC, Lau YL, Ha SY, Chiang AK: Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Mar;50(3):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
  • Salivary gland tumors account for about 6% of the second cancers.
  • The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland.
  • We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor.
  • The behavior of secondary ACC appears similar to primary tumor and similar treatment may be adopted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Acinar Cell / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16865683.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; UKALL X protocol
  • [Number-of-references] 17
  •  go-up   go-down


67. Chen AM, Garcia J, Granchi PJ, Johnson J, Eisele DW: Late recurrence from salivary gland cancer: when does "cure" mean cure? Cancer; 2008 Jan 15;112(2):340-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1960 and 2000, 145 patients underwent definitive therapy for localized carcinomas of the salivary glands and were clinically without evidence of disease at 5 years of follow-up.
  • RESULTS: The 10-year and 15-year cumulative probabilities of late recurrence in patients who were free of disease at 5 years were 13% and 18%, respectively.
  • The crude rates of late recurrence by histologic subtype were adenoid cystic carcinoma (26%), mixed malignant tumor (25%), mucoepidermoid carcinoma (17%), adenocarcinoma (10%), and acinic cell carcinoma (8%).
  • Salvage treatment varied according to location of disease recurrence and initial treatment characteristics.
  • The 15-year estimate of overall survival was 39% for patients who experienced a late recurrence compared with 71% for those who remained free of disease (P= .001).
  • CONCLUSIONS: A significant proportion of patients who are presumed to be cured of their disease at 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrence with additional follow-up.


68. van Tongeren J, Creytens DH, Meulemans EV, de Bondt RB, de Jong J, Manni JJ: Synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland: case report and review of the literature. Eur Arch Otorhinolaryngol; 2009 Sep;266(9):1495-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland: case report and review of the literature.
  • The most common synchronous bilateral malignancies are acinic cell carcinoma.
  • Epithelial-myoepithelial carcinoma is an uncommon neoplasm comprising 1% of all salivary gland tumours.
  • In this case report, we describe, to our best of knowledge, the first case of a patient with a synchronous bilateral epithelial-myoepithelial carcinoma of the parotid gland.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • Genetic Alliance. consumer health - Epithelial-Myoepithelial Carcinoma.
  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Oral Maxillofac Surg. 2006 Oct;44(5):397-401 [16207507.001]
  • [Cites] Oral Oncol. 2006 Feb;42(2):154-60 [16256413.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Arch Surg. 1975 Jan;110(1):64-8 [1090282.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):258-63 [10966568.001]
  • [Cites] J Laryngol Otol. 2001 May;115(5):434-6 [11410145.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] Auris Nasus Larynx. 2003 May;30(2):201-3 [12753995.001]
  • [Cites] J Laryngol Otol. 2003 May;117(5):419-21 [12803799.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):613-9 [15153875.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):531-4 [15308250.001]
  • [Cites] Am J Surg. 1969 Nov;118(5):787-9 [4310431.001]
  • [Cites] Ann Surg. 1969 Nov;170(5):866-9 [5347563.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1972;356(1):16-31 [4340536.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1978;40(2):120-6 [570688.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Mar;53(3):280-7 [6950345.001]
  • [Cites] Laryngoscope. 1988 Jan;98(1):99-105 [3336269.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Jun;101(6):540-2 [1376977.001]
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):358-63 [1322017.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):389-96 [8322454.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):421-5 [7511356.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):432-7 [7726139.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Surg Oncol. 1997 Dec;6(4):209-13 [9775407.001]
  • [Cites] AMA Arch Pathol. 1953 Apr;55(4):328-46 [13030050.001]
  • [Cites] Plast Reconstr Surg Transplant Bull. 1959 Jan;23(1):55-63 [13633480.001]
  • [Cites] J Laryngol Otol. 1961 Jul;75:699-702 [13722582.001]
  • [Cites] Mod Pathol. 2005 May;18(5):645-50 [15529180.001]
  • [Cites] Head Neck. 2005 Sep;27(9):825-8 [15920750.001]
  • [Cites] Oral Oncol. 2006 Jan;42(1):57-65 [16140564.001]
  • [Cites] Int J Surg Pathol. 2006 Jul;14(3):212-7 [16959701.001]
  • (PMID = 18841376.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 35
  • [Other-IDs] NLM/ PMC2718197
  •  go-up   go-down


69. Luna MA: Sinonasal tubulopapillary low-grade adenocarcinoma: a specific diagnosis or just another seromucous adenocarcinoma? Adv Anat Pathol; 2005 May;12(3):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal tubulopapillary low-grade adenocarcinoma: a specific diagnosis or just another seromucous adenocarcinoma?
  • Histopathologically, sinonasal adenocarcinomas fall into four categories: the intestinal type, the conventional salivary gland type (eg, adenoid cystic carcinoma, acinic cell carcinoma), the seromucous type, and the low-grade not otherwise specified type.
  • Recently, a new type of sinonasal adenocarcinoma has been described, called tubulopapillary low-grade adenocarcinoma.
  • In this commentary, the histologic features of this type of tumor are compared with those of the other types of sinonasal adenocarcinoma.
  • The clinicopathologic characteristics and probable origin of this type of adenocarcinoma are also discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Paranasal Sinus Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Virchows Arch. 2003 Aug;443(2):152-8 [12827515.001]
  • (PMID = 15900111.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Vakiani E, Young RH, Carcangiu ML, Klimstra DS: Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases. Am J Surg Pathol; 2008 Oct;32(10):1540-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas metastatic to the ovary: a report of 4 cases.
  • We report 4 cases of acinar cell carcinoma of the pancreas, 3 presenting as metastases in the ovary, the first report of this circumstance, which may pose a broad differential diagnosis and caused significant diagnostic difficulty in all the cases.
  • In 3 cases, the ovarian tumors were detected before the pancreatic tumor; in 1 case, a large abdominal mass and ovarian tumors were discovered synchronously.
  • The ovarian tumors were large, solid, white-tan on gross examination, and bilateral in 3 cases; the single case involving only 1 ovary had 2 discrete masses of tumor.
  • Two cases had a predominant acinar growth pattern of cells with brightly eosinophilic, granular cytoplasm.
  • The main differential diagnostic consideration was well-differentiated neuroendocrine neoplasm (carcinoid tumor); positive immunostaining with antibodies against chymotrypsin and trypsin and negative immunostaining with antibodies against synaptophysin and chromogranin helped exclude this diagnosis.
  • We observed focal alpha-inhibin immunostaining in 2 cases, which may represent a potential diagnostic pitfall, as a Sertoli cell tumor or unusual granulosa cell tumor may also enter the differential diagnosis.
  • Inclusion of antibodies against the pancreatic enzymes chymotrypsin and trypsin in the immunohistochemical panel is critical in establishing the correct diagnosis and should be considered when evaluating ovarian tumors with architectural (mainly acinar) and cytologic (granular eosinophilic cytoplasm) characteristics that should bring a metastatic acinar cell carcinoma into consideration.
  • [MeSH-major] Carcinoma, Acinar Cell / secondary. Ovarian Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724247.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Lipsett MA, Castellarin ML, Rosenberg L: Acinar plasticity: development of a novel in vitro model to study human acinar-to-duct-to-islet differentiation. Pancreas; 2007 May;34(4):452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar plasticity: development of a novel in vitro model to study human acinar-to-duct-to-islet differentiation.
  • It has previously been shown that pancreatic islet-to-duct transformation and acinoductal metaplasia have been associated with both pancreatic regeneration and adenocarcinoma in various in vivo and in vitro settings.
  • Understanding this inherent morphogenetic plasticity of the adult pancreas could lead to new therapeutic approaches to pancreatic disease.
  • METHODS: Cadaveric human pancreases (n = 7) were digested, and purified acinar tissue, which was approximately 85% immunoreactive for amylase and approximately 15% immunoreactive for CK-19, was embedded in a type 1 collagen matrix and cultured in a differentiation medium (DM) consisting of Dulbecco modified Eagle/F12 medium supplemented with cholera toxin (100 ng/mL), epidermal growth factor (10 ng/mL), and insulin (24 mU/mL) for 8 days.
  • However, when acinar-derived ductlike structures were cultured with gastrin + HGF + INGAP, the total incidence of dithizone-positive structures increased approximately 6-fold (10.9 +/- 2.9% vs 1.7 +/- 0.4%, P = 0.037).
  • CONCLUSIONS: We have developed a novel in vitro model of adult human acinoductal metaplasia that will aid not only in developing new methods of expanding beta-cell mass but also provide insights into pancreatic carcinogenesis.
  • [MeSH-major] Cell Differentiation. Islets of Langerhans / pathology. Pancreatic Ducts / pathology. Regeneration
  • [MeSH-minor] Adult. Amylases / metabolism. C-Peptide / metabolism. Cell Proliferation. Cells, Cultured. Cytokines / pharmacology. Gastrins / pharmacology. Hepatocyte Growth Factor / pharmacology. Homeodomain Proteins / biosynthesis. Humans. Insulin-Secreting Cells / pathology. Keratin-19 / metabolism. Metaplasia. Pancreas / pathology. Pancreas / physiopathology. Peptide Fragments / pharmacology. Phenotype. Time Factors. Trans-Activators / biosynthesis. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17446845.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C-Peptide; 0 / Cytokines; 0 / Gastrins; 0 / Homeodomain Proteins; 0 / INGAP peptide; 0 / Keratin-19; 0 / Peptide Fragments; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein; 67256-21-7 / Hepatocyte Growth Factor; EC 3.2.1.- / Amylases
  •  go-up   go-down


72. Shen JX, Fan WJ, Lu YC, Xiao P: [Malignant epithelial parotid tumors: CT imaging and histopathologic correlation]. Ai Zheng; 2007 Jul;26(7):762-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant epithelial parotid tumors: CT imaging and histopathologic correlation].
  • BACKGROUND & OBJECTIVE: Malignant epithelial parotid tumors have various histopathologic types.
  • This study was to analyze CT features of malignant epithelial parotid tumors to evaluate the diagnostic value of CT in the characterization of malignant epithelial parotid tumors.
  • METHODS: CT reports of 29 patients with malignant epithelial parotid tumors (8 at low grade and 21 at intermediate or high grade), confirmed by histopathology in Cancer Center of Sun Yat-sen University, were reviewed.
  • RESULTS: Of the 8 cases at low grade, 4 were well-differentiated mucoepidermoid carcinoma, 3 were acinic cell carcinoma, and 1 was epithelial-myoepithelial carcinoma; 3 had sharp margin, 3 had partly unsharp margin, and 2 had unsharp margin; 5 had regular contour, and 3 had irregular contour; all were enhanced obviously; 2 showed homogeneous appearance, and 6 showed inhomogeneous appearance with low-density areas; none had adjacent infiltration; 3 had lymph node metastasis.
  • Of the 21 cases at intermediate or high grade, 5 were poorly-differentiated squamous cell carcinoma, 8 were malignant pleomorphic adenoma, 2 were adenocarcinoma, 1 was lymph-epithelial carcinoma, 4 were mucoepidermoid carcinoma, and 1 was adenoidcystic carcinoma; 5 had sharp margin, 7 had partly unsharp margin, and 9 had unsharp margin; 10 had regular contour, and 11 had irregular contour; 17 were enhanced obviously, and the 4 cases of malignant pleomorphic adenoma were enhanced slightly; 9 showed homogeneous appearance, and 12 showed inhomogeneous appearance with low-density areas; 8 had adjacent infiltration (the fat space between tumor and the parotid bed disappeared); 6 had lymph node metastasis.
  • CONCLUSIONS: To some extent, CT features of malignant epithelial parotid tumors are correlated to the differentiation of tumor cells.
  • Moreover, tumor size and histologic subtype should be considered to make a more accurate imaging diagnosis.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / radiography. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / radiography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Parotid Gland / pathology. Parotid Gland / radiography. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626755.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


73. Machado MC, Machado MA, Perini MV, Herman P, Jukemura J, Leite KR, Bacchella T: Acinar cell carcinoma of the pancreas: is the absence of neuroendocrine component related to a more malignant behavior? Hepatogastroenterology; 2008 Mar-Apr;55(82-83):708-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas: is the absence of neuroendocrine component related to a more malignant behavior?
  • BACKGROUND/AIMS: Acinar cell carcinomas are uncommon malignant tumors of the pancreas, accounting for 1-2% of all the cases of exocrine pancreatic tumor.
  • Some authors have estimated acinar cell tumors to be as aggressive as ductal adenocarcinoma of the pancreas whereas other series showed acinar cell tumors to have a favorable clinical outcome.
  • This discrepancy in prognosis may be related to the cellular components of the tumor.
  • METHODOLOGY: With the aim to evaluate the possible relationship between the presence of neuroendocrine differentiation and behavior of these tumors, the authors reviewed all patients presenting acinar cell carcinoma of the pancreas in the last 5 years with emphasis in the immunohistochemical evaluation.
  • Two patients without neuroendocrine component had a disseminated disease at presentation.
  • This data suggests that this tumor is less aggressive than ductal adenocarcinoma and even with nodal involvement, long-term survival after complete resection can be achieved.
  • Due to the rarity of this pancreatic tumor, this relationship remains to be confirmed with a multicentric study including a larger number of patients.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613439.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


74. Imamura M, Kimura Y, Ito H, Nobuoka T, Koito K, Sasaki A, Hirata K: Acinar cell carcinoma of the pancreas with intraductal growth: report of a case. Surg Today; 2009;39(11):1006-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas with intraductal growth: report of a case.
  • Acinar cell carcinomas (ACCs) of the pancreas are rare neoplasms, accounting for approximately 1% of all exocrine pancreatic tumors.
  • This type of tumor is known to be aggressive, although the survival rates are somewhat better than they are for ductal carcinoma.
  • The tumor tends to present nonspecific symptoms.
  • [MeSH-major] Carcinoma, Acinar Cell / surgery. Neoplasm Invasiveness. Pancreatectomy / methods. Pancreatic Ducts / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Endosonography. Female. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Feb 15;59(4):739-47 [3542187.001]
  • [Cites] Virchows Arch. 2001 Mar;438(3):312-5 [11315630.001]
  • [Cites] Surg Today. 2007;37(8):704-7 [17643220.001]
  • [Cites] Pancreas. 2003 Apr;26(3):306-8 [12657959.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jan;16(1):107-11 [11206307.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):363-70 [17325477.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):410-6 [7459828.001]
  • (PMID = 19882327.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Aydin H, Zhang J, Samaratunga H, Tan N, Magi-Galluzzi C, Klein E, Jones JS, Zhou M: Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU Int; 2010 Feb;105(4):476-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management.
  • OBJECTIVE: To report the clinicopathological characteristics of 23 cases of ductal adenocarcinoma of the prostate (DCP) and discuss the implications for clinical management, as DCP is considered an aggressive subtype of prostate adenocarcinoma (PA).
  • The study included 23 cases of pure DCP without acinar PA diagnosed on UB or TURP.
  • CONCLUSIONS: Most DCP diagnosed on UB or TURP in this contemporary series was associated with aggressive PA, but a subset presented as a small periurethral tumour with no concomitant acinar PA, and was eradicated by the initial biopsy/TURP alone.
  • We recommend that patients with a diagnosis of DCP on UB or TURP undergo follow-up TURP and TRUSB before radical surgery is offered.
  • [MeSH-major] Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709071.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


76. Mallén E, Gil P, Sancho C, Jesús Gil M, Allepuz C, Borque A, Del Agua C, Angel Rioja L: Atypical small acinar proliferation: review of a series of 64 patients. Scand J Urol Nephrol; 2006;40(4):272-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: review of a series of 64 patients.
  • OBJECTIVE: To study the evolution of 64 patients initially diagnosed with ASAP (atypical small acinar proliferation).
  • At re-biopsy, we diagnosed 27 patients (42%) with prostate adenocarcinoma.
  • CONCLUSIONS: In our experience, a pathological result of ASAP is associated with a definitive diagnosis of prostate cancer in 42% of cases.
  • [MeSH-major] Prostatic Diseases / diagnosis
  • [MeSH-minor] Aged. Biopsy. Cell Proliferation. Humans. Male. Prostate-Specific Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916766.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


77. Yamada Y, Hiraoka N: A case of acinar cell adenocarcinoma in the pancreatic tail. Jpn J Clin Oncol; 2006 Jul;36(7):473
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of acinar cell adenocarcinoma in the pancreatic tail.
  • [MeSH-major] Carcinoma, Acinar Cell / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887840.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Kuroda N, Hamaguchi N, Takeuchi E, Ohara M, Hirouchi T, Mizuno K: Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS; 2006 May;114(5):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases.
  • Lung adenocarcinoma with a micropapillary pattern has recently been described, but its biological behavior is as yet uncertain.
  • In this article we present a clinicopathological study of lung adenocarcinoma with micropapillary morphology.
  • We selected 25 patients with lung adenocarcinoma with micropapillary morphology from the 2001-2004 pathology files (age range 54 to 81 years; mean 64.5 years).
  • Micropapillary carcinoma is predominantly located at the periphery of the tumor nodule or mass and occurs irrespective of the subtype of the adenocarcinoma.
  • Four cases showed intensive invasive growth such as micropapillary adenocarcinoma of the breast and 21 showed alveolar type morphology with piling-up of the neoplastic cells with or without stromal invasion.
  • Regarding clinical outcome, 14 patients were alive without disease, 5 were alive with disease, and 5 died of the lung adenocarcinoma.
  • However, the carcinoma seen in the five patients who died showed breast type histology with intensive invasive growth in three cases and alveolar type histology with intensive stromal invasion in two.
  • Lung micropapillary carcinoma of breast type may behave more aggressively than the alveolar type.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Aged. Aged, 80 and over. Calcinosis / pathology. Carcinoma, Acinar Cell / pathology. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pleura / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725015.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


79. Kebir FZ, Lahmar A, Arfa N, Manai S, El Ouaer MA, Bouraoui S, Gouttalier C, Mezabi-Regaya S: Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):103-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma of the pancreas in a young patient with chronic pancreatitis.
  • BACKGROUND: Acinar cell carcinoma (ACC) is a rare malignancy of the pancreas arising from acinar cells.
  • Unlike ductal adenocarcinoma, this tumor rarely presents with pancreatitis.
  • METHODS: We present a case of ACC associated with chronic calcifying pancreatitis, and a review of the literature focusing on diagnosis and management.
  • CONCLUSIONS: The clinical presentation of ACC of the pancreas is not specific and the tumor can be under-diagnosed when associated with chronic pancreatitis.
  • Data regarding course, treatment, and prognosis of this tumor are generally lacking.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / complications

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133240.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec JY: Primary acinar cell carcinoma of the liver. Virchows Arch; 2008 Mar;452(3):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the liver.
  • We report a case of acinar cell carcinoma primary to the liver.
  • The tumor was diagnosed in a 35-year-old woman complaining of abdominal pain and asthenia; serum alpha-fetoprotein (AFP) levels were increased at 6,000 IU/mL; imaging studies showed a hypervascular mass located in the left lobe of the liver.
  • The tumor had a heterogeneous appearance.
  • In well-differentiated areas, tumor cells formed acinar structures, had a pyramidal shape and a highly eosinophilic, granular cytoplasm, PAS diastase resistant.
  • In less-differentiated areas, tumor cells were endocrinelike.
  • The immunohistochemical study showed that tumor cells expressed trypsin.
  • The final diagnosis, based on histological, immunohistochemical, and ultrastructural arguments, was extra-pancreatic acinar cell carcinoma, primary to the liver.
  • This unusual lesion is likely to be the result of an abnormal differentiation pathway involving a transformed multipotential progenitor cell.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Liver / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S94-112 [17486055.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Pancreas. 2007 Jul;35(1):42-6 [17575544.001]
  • [Cites] Indian J Med Sci. 1979 Jun;33(6):157-9 [521108.001]
  • [Cites] Surg Today. 2007;37(8):704-7 [17643220.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1524-9 [16224221.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):263-5 [14991547.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jul-Aug;9(4):312-5 [16944990.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):203-9 [10981872.001]
  • [Cites] Hum Pathol. 2002 May;33(5):569-73 [12094386.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):938-44 [10987254.001]
  • [Cites] Trends Endocrinol Metab. 2003 Dec;14(10):460-6 [14643061.001]
  • [Cites] Hepatogastroenterology. 1992 Jun;39(3):282-6 [1380476.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):707-11 [10420228.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31950-7 [12775714.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):449-51 [12055683.001]
  • (PMID = 18193278.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / alpha 1-Antitrypsin; 0 / alpha-Fetoproteins
  •  go-up   go-down


81. Volkan Adsay N: Cystic lesions of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S71-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cystic tumors of the pancreas are relatively rare, they constitute an increasingly important category.
  • Consequently, in the past two decades, the nature of many cystic tumors in this organ has been better characterized.
  • The names of some existing entities were revised; for example, what was known as papillary-cystic tumor is now regarded as solid-pseudopapillary tumor.
  • The importance of clinical and pathologic correlation in the evaluation of these lesions was appreciated, in particular, with regards to the multifocality of these lesions, their association with invasive carcinomas, and thus their 'preinvasive' nature.
  • Consensus criteria for the distinction of these from the ordinary precursors of adenocarcinoma, the pancreatic intraepithelial neoplasia, were established.
  • The definition of mucinous cystic neoplasms was refined; ovarian-like stroma has now become almost a requirement for the diagnosis of mucinous cystic neoplasia, and defined as such, the propensity of these tumors to occur in perimenopausal women became even more striking.
  • Greater accessibility of the pancreas afforded by improved invasive as well as noninvasive modalities has also increased the detection of otherwise clinically silent cystic tumors, which has led to the recognition of more innocuous entities such as acinar cell cystadenoma and squamoid cyst of pancreatic ducts.
  • As the significance of the cystic lesions emerged, cystic forms of otherwise typically solid tumors were also better characterized.
  • Thus, significant developments have taken place in the classification and our understanding of pancreatic cystic tumors in the past few years, and experience with these lesions is likely to grow exponentially in the coming years.
  • [MeSH-minor] Adenoma / pathology. Carcinoma in Situ / pathology. Humans. Pancreatic Ducts / pathology. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486054.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Dessimoz J, Grapin-Botton A: Pancreas development and cancer: Wnt/beta-catenin at issue... Cell Cycle; 2006 Jan;5(1):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This raises the question of the cell type in which beta-catenin is mutated during tumor formation in acinar cell carcinomas, pancreatoblastomas and solid cystic papillary tumors of the pancreas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322692.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


83. Psalla D, Geigy C, Konar M, Café Marçal V, Oevermann A: Nasal acinic cell carcinoma in a cat. Vet Pathol; 2008 May;45(3):365-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal acinic cell carcinoma in a cat.
  • This case report describes the clinical, magnetic resonance imaging (MRI)-related, and pathologic features of a nasal acinic cell carcinoma in a cat.
  • Evaluation by MRI revealed an heterogeneous, space-occupying lesion that filled the left nasal cavity and was diagnosed by histopathologic examination as an acinic cell carcinoma arising from a minor salivary gland of the nasal cavity.
  • Acinic cell carcinoma is a rare tumor in veterinary medicine.
  • The tumor is composed mainly of cells resembling serous cells of salivary glands and originates from major or minor salivary glands.
  • Clinicians and pathologists should be aware of the occurrence of acinic cell carcinoma in the sinonasal tract and include the tumor in the differential diagnosis of feline nasal diseases.
  • [MeSH-major] Carcinoma, Acinar Cell / veterinary. Paranasal Sinus Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487495.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


84. Vazquez MF, Koizumi JH, Henschke CI, Yankelevitz DF: Reliability of cytologic diagnosis of early lung cancer. Cancer; 2007 Aug 25;111(4):252-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability of cytologic diagnosis of early lung cancer.
  • Among them, 65 people had surgical resection of their screen-diagnosed lung cancer, 53 of them on the basis of a diagnosis of malignancy or atypical bronchioloalveolar proliferation (ABP) on fine needle aspiration (FNA) biopsy at Weill Medical College of Cornell University (WMC) prior to surgery.
  • The authors compared the diagnosis obtained from the FNA with the subsequent diagnosis from the surgical specimen to assess the reliability of a cytologic diagnosis of lung cancer on FNA of these screen-diagnosed lung cancers.
  • ), with preliminary on-site as well as final diagnosis rendered by a cytologist (M.V., J.K.).
  • These results were correlated with histologic diagnoses obtained as a result of consensus diagnosis by a panel of 5 expert pulmonary pathologists.
  • RESULTS: Of the 53 cases of lung cancer resected following FNA, 4 were diagnosed as atypical bronchioloalveolar proliferation (ABP), 14 as adenocarcinoma with bronchioloalveolar features (ADC-BAC), 28 as adenocarcinoma, not otherwise specified (ADC-NOS), 1 as squamous cell carcinoma (SQCC), 4 as nonsmall-cell carcinoma (NSCC), and 2 as typical carcinoid.
  • In the 49 cases with a malignant cytology and 4 cases of ABP, lung cancer was confirmed histologically.
  • The tumor sizes ranged from 4 mm to 40 mm, mean size 13mm.
  • The final expert panel histologic diagnosis was adenocarcinoma in 47 cases; of these, 42 were invasive (mixed subtype or acinar subtype), and 5 were a noninvasive (bronchioloalveolar carcinoma, BAC).
  • Three of the 42 invasive adenocarcinoma that had a predominant BAC component and 1 case of BAC were diagnosed as ABP on FNA; all were sampled at the periphery of the tumor.
  • Three of 4 cases of invasive adenocarcinoma of high nuclear grade were diagnosed as NSCC, and 1 was inaccurately classified as SQCC on FNA.
  • Two cases classified as nonkeratinizing SQCC and 2 cases of large cell neuroendocrine carcinoma on histology were misclassified as ADC-NOS by FNA.
  • CONCLUSIONS: Preoperative diagnosis of lung cancer detected by screening with HRCT could be reliably made by FNA.
  • Difficulty in classification occurs in carcinomas of high nuclear grade with prominent nucleoli, including poorly differentiated SQCC and large cell neuroendocrine carcinoma.
  • These are best diagnosed as NSCC on cytomorphology with further subclassification based on immunohistochemistry, which these authors generally perform on cell-block material.
  • A diagnosis of ABP on FNA may be indicative of noninvasive BAC or an invasive adenocarcinoma with prominent BAC features, usually sampled at its periphery.
  • [MeSH-major] Biopsy, Fine-Needle. Cytodiagnosis / methods. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoid Tumor / diagnosis. Carcinoma, Non-Small-Cell Lung / diagnosis. Humans. Neoplasms, Squamous Cell / diagnosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 May 15;112(10):2329-30 [18407546.001]
  • (PMID = 17614298.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Hughes JH, Volk EE, Wilbur DC, Cytopathology Resource Committee, College of American Pathologists: Pitfalls in salivary gland fine-needle aspiration cytology: lessons from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med; 2005 Jan;129(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 6249 participant responses with general interpretations of benign (n = 4642) or malignant (n= 1607) were reviewed.
  • The sensitivity and specificity of the participant responses for correctly interpreting the cases as benign or malignant were 73% and 91%, respectively.
  • Malignant cases with the highest false-negative rates were lymphoma (57%), acinic cell carcinoma (49%), low-grade mucoepidermoid carcinoma (43%), and adenoid cystic carcinoma (33%).
  • [MeSH-major] Cytodiagnosis / standards. Databases, Factual. Diagnostic Errors. Gynecology. Pathology, Clinical / standards. Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2005 Dec;129(12):1522; author reply 1522 [16329719.001]
  • [CommentIn] Arch Pathol Lab Med. 2006 Oct;130(10):1428; author reply 1428 [17090178.001]
  • (PMID = 15628905.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Cavallini A, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G: Pancreatoblastoma in adults: a review of the literature. Pancreatology; 2009;9(1-2):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given the rarity of the disease, the aim of this study was to review our personal experience with adult pancreatoblastoma as well as the cases reported in the literature in order to support clinicians observing this entity.
  • The diagnosis of pancreatoblastoma mainly depends on the pathological findings characterized by squamoid corpuscles at histopathology.
  • Both our patients are disease free after 15 months (case 2) and 51 months (case 1).
  • The latter represents the most successful result in long-term disease-free survival.
  • The differential diagnosis includes nonfunctional pancreatic endocrine tumor, acinar cell carcinoma, solid pseudopapillary tumor and adenocarcinoma.
  • Chemotherapy may play a role as palliative treatment in advanced disease.
  • [MeSH-major] Carcinoma, Neuroendocrine. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Humans. Male. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel and IAP.
  • (PMID = 19077457.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


87. Zhang S, Bao R, Abreo F: Papillary oncocytic cystadenoma of the parotid glands: a report of 2 cases with varied cytologic features. Acta Cytol; 2009 Jul-Aug;53(4):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis ofa neoplasm was rendered and excisional biopsy recommended.
  • Warthin's tumor, oncocytoma, intraductal papilloma and acinic cell carcinoma may arise in the differential diagnosis.
  • In cases with extensive necrotic debris and metaplastic squamous cells, branchial cyst and cystic metastatic squamous carcinoma may also need to be considered.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697734.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK: Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res; 2006 Dec 15;12(24):7353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of methylation patterns of cancer genes in salivary gland tumors.
  • PURPOSE: We investigated the methylation status and protein expression of four tumor suppressor genes to determine their role in salivary gland tumorigenesis.
  • EXPERIMENTAL DESIGN: We performed methylation-specific PCR and protein analyses of 29 normal salivary glands, 23 benign, and 79 malignant salivary gland neoplasms to determine the pattern and potential diagnostic and/or biological role of the RASSF1, RARbeta2, DAPK, and MGMT tumor suppressor gene methylation in these tumors.
  • Methylation occurred in 9 of 23 (39.1%) benign tumors; 3 (25.0%) pleomorphic adenomas and 6 (66.7%) Warthin's tumors at the MGMT, DAPK, or RASSF1 genes.
  • Methylation occurred in 33 of 79 (41.8%) malignant tumors; 8 (30.8%) adenoid cystic carcinomas, 6 (33.3%) mucoepidermoid carcinomas, 6 (42.9%) acinic cell carcinomas, and 13 (62.0%) salivary duct carcinomas.
  • RASSF1 and RARbeta2 represented 75.8% of methylation events occurring most frequently in salivary duct and acinic cell carcinomas.
  • Overall, we found no significant correlation between protein expression and methylation status of individual genes, but observed low or absent protein expression in several methylated tumors.
  • Significant correlations were found between methylation and aggressive malignant phenotypes (P = 0.0004) and age (P = 0.05).
  • CONCLUSIONS: (a) Benign and malignant salivary tumors differed in the frequency and pattern of gene methylation;.
  • (b) high-grade carcinomas were significantly methylated compared with low-grade phenotypes;.
  • (c) RASSF1 and RARbeta2 were highly methylated in malignant tumors and can be targeted for therapy; and (d) methylation pattern may serve as a diagnostic and biological marker in assessing these tumors.
  • [MeSH-major] Carcinoma / metabolism. DNA Methylation. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / metabolism. Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Child. DNA Modification Methylases. DNA Repair Enzymes. Death-Associated Protein Kinases. Female. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Receptors, Retinoic Acid / metabolism. Tumor Suppressor Protein p14ARF / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189407.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


89. Zhang N, Lyons S, Lim E, Lassota P: A spontaneous acinar cell carcinoma model for monitoring progression of pancreatic lesions and response to treatment through noninvasive bioluminescence imaging. Clin Cancer Res; 2009 Aug 1;15(15):4915-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A spontaneous acinar cell carcinoma model for monitoring progression of pancreatic lesions and response to treatment through noninvasive bioluminescence imaging.
  • PURPOSE: We have generated an EL1-luc/TAg transgenic mouse model that develops spontaneous and bioluminescent acinar cell carcinomas.
  • We applied this model to noninvasively monitor tumor development and drug response.
  • Tumor development was monitored through bioluminescence imaging and necropsy at the study end point.
  • RESULTS: EL1-luc/TAg transgenic mice showed pancreas-specific bioluminescence signal before tumor progression and produced increasing light emission from the onset of the pancreatic acinar cell carcinomas.
  • The latency of tumor development ranged from 10 to >20 weeks of age in these mice.
  • Progression of the primary acinar cell carcinoma was accompanied by emergence of metastatic lesions in the abdominal organs, including liver and gastrointestinal fat tissues.
  • Rapamycin treatment suppressed tumor development.
  • CONCLUSIONS: The EL1-luc/TAg mouse provides a noninvasive approach for monitoring spontaneous acinar cell carcinoma development and comprises a convenient tool for the evaluation of novel therapeutics against pancreatic cancers.
  • Tumor growth suppression through inhibition of the mammalian target of rapamycin pathway further validates this model as clinically relevant.
  • [MeSH-major] Antibiotics, Antineoplastic / metabolism. Carcinoma, Acinar Cell / metabolism. Drug Monitoring. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Longitudinal Studies. Luminescent Measurements. Mice. Mice, Transgenic. Sirolimus / metabolism. Sirolimus / therapeutic use


90. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH: Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol; 2005 Jun;18(6):752-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways.
  • Solid pseudopapillary tumor, pancreatoblastoma, undifferentiated carcinoma with osteoclastic-like giant cells, and acinar cell carcinomas are rare pancreatic nonductal neoplasms.
  • Compared to the significant advances in our understanding of the pathogenesis of pancreatic ductal adenocarcinomas in the last decades, the molecular mechanisms underlying pancreatic nonductal neoplasms are poorly understood.
  • In order to elucidate their molecular pathogenesis, we constructed tissue microarrays to study the expression of some novel pancreatic ductal adenocarcinoma-associated tumor markers in these nonductal pancreatic neoplasms.
  • We analyzed nine markers including tumor suppressor gene (14-3-3 sigma), proliferation marker (topoisomerase II alpha), epithelial markers (prostate stem cell antigen, mesothelin and cytokeratin 19), stromal markers (fascin, hsp47 and fibronectin), and gamma-synuclein whose function is not delineated.
  • In addition, we included tumor suppressor gene DPC4 and oncogene Beta-catenin to further confirm their expression in pancreatic nonductal tumors.
  • Our results showed that in contrast to pancreatic ductal adenocarcinomas that show loss of Dpc4 protein in 55% of cases, loss of Dpc4 expression is absent in pancreatic nonductal neoplasms.
  • Expression of 14-3-3 sigma is frequently seen in both pancreatic nonductal neoplasms (25-100%) and ductal adenocarcinomas (89%).
  • Aberrant nuclear expression of beta-catenin is common in pancreatic nonductal neoplasms, specifically in solid pseudopapillary tumors (88%) and pancreatoblastomas (100%) but is rarely seen in pancreatic ductal adenocarcinomas (<5%).
  • Expression of topoisomerase II alpha is not seen in solid pseudopapillary tumors and undifferentiated carcinomas with osteoclastic-like giant cells but is focally seen in pancreatoblastomas (50%) and acinar cell carcinomas (85%).
  • Expression of PSCA and mesothelin was observed in pancreatic nonductal neoplasms but their expression was seen less frequently (0-50%) and weaker than that in pancreatic ductal adenocarcinomas (60-100%).
  • CK19, a marker of pancreatic ductal adenocarcinomas, is not expressed in pancreatic nonductal neoplasms.
  • Our findings indicate pancreatic nonductal neoplasms have distinctive patterns of protein expression relative to pancreatic ductal adenocarcinomas and suggest that pancreatic nonductal neoplasms have different genetic pathways from the more common pancreatic ductal adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] 14-3-3 Proteins. Antigens, Neoplasm. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carrier Proteins / analysis. Cytoskeletal Proteins / analysis. DNA-Binding Proteins / analysis. Exonucleases / analysis. Exoribonucleases. Fibronectins / analysis. GPI-Linked Proteins. HSP47 Heat-Shock Proteins. Heat-Shock Proteins / analysis. Humans. Immunohistochemistry. Keratins / analysis. Membrane Glycoproteins / analysis. Microfilament Proteins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis. Serpins / analysis. Smad4 Protein. Synucleins. Trans-Activators / analysis. beta Catenin. gamma-Synuclein

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696124.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Fibronectins; 0 / GPI-Linked Proteins; 0 / HSP47 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / PSCA protein, human; 0 / SERPINH1 protein, human; 0 / SMAD4 protein, human; 0 / Serpins; 0 / Smad4 Protein; 0 / Synucleins; 0 / Trans-Activators; 0 / beta Catenin; 0 / gamma-Synuclein; 0 / mesothelin; 146808-54-0 / fascin; 68238-35-7 / Keratins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


91. Luukkaa H, Klemi P, Hirsimäki P, Vahlberg T, Kivisaari A, Kähäri VM, Grénman R: Matrix metalloproteinase (MMP)-7 in salivary gland cancer. Acta Oncol; 2010;49(1):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The study population of 107 patients consisted of 47 male and 60 female subjects, ranging in age at the time of diagnosis between 23 and 90 years.
  • By age-adjusted analysis lower staining intensity was associated with worse overall survival of patients with acinic cell carcinoma (p = 0.047, HR 6.5, 95% Cl 1.0-41.7) and in mucoepidermoid carcinoma (p = 0.010, HR 9.3, 95% CI 1.7-50.0).
  • Low staining intensity was also associated with worse disease-specific survival of patients with acinic cell carcinoma (0-1 vs. 2-3; p = 0.047, HR 13.7, 1.0-200.0).
  • CONCLUSIONS: MMP-7 is associated with the prognosis of patients with acinic cell and mucoepidermoid carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / metabolism. Carcinoma, Mucoepidermoid / metabolism. Matrix Metalloproteinase 7 / biosynthesis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929564.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


92. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene; 2005 Jun 23;24(27):4421-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma.
  • In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cycler quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens.
  • By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas.
  • Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors).
  • Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four.
  • [MeSH-minor] Cell Line, Tumor. Fluorouracil / pharmacology. Humans. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856026.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR: Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell; 2010 Nov 16;18(5):499-509
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We find in a murine model of familial pancreatic cancer that germline heterozygosity for a pathogenic Brca2 truncation suffices to promote pancreatic ductal adenocarcinomas (PDACs) driven by Kras(G12D), irrespective of Trp53 status.
  • Unexpectedly, tumor cells retain a functional Brca2 allele.
  • Three tumors from these patients displaying LOH were acinar carcinomas, which also developed only in mice with biallelic Brca2 inactivation.
  • We suggest a revised model for tumor suppression by BRCA2 with implications for the therapeutic strategy targeting BRCA2 mutant cancer cells.
  • [MeSH-major] BRCA2 Protein / genetics. Carcinoma, Pancreatic Ductal / genetics. Disease Models, Animal. Genes, BRCA2. Germ-Line Mutation. Heterozygote. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins p21(ras) / genetics
  • [MeSH-minor] Alleles. Animals. Cell Line, Tumor. Codon, Nonsense. Gene Silencing. Loss of Heterozygosity. Mice. Mice, 129 Strain. Mice, Inbred C57BL. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21056012.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359877; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G9900064; United Kingdom / Medical Research Council / / G0600332; United Kingdom / Medical Research Council / / G0700651
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA2 Protein; 0 / Codon, Nonsense; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


94. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. Int J Biol Markers; 2006 Oct-Dec;21(4):201-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors.
  • Human kallikrein 3 (hK3; prostate-specific antigen) is the most useful marker for adenocarcinoma of the prostate gland.
  • The aim of this study was to determine whether hK3 and hK5 are expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), in order to compare normal with tumor tissues.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.
  • The results of this study indicate that most salivary gland tumors do not show high levels of expression of hK5.
  • Staining was most prominent in keratinizing epithelia in pleomorphic adenomas. hK3 is not expressed in salivary gland tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Kallikreins / analysis. Prostate-Specific Antigen / analysis. Salivary Gland Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177156.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 5, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


95. Osunkoya AO, Nielsen ME, Epstein JI: Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol; 2008 Mar;32(3):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
  • Mucinous adenocarcinoma of the prostate is one of the least common variants of prostate cancer.
  • We present 47 cases (1991 to 2006) of mucinous carcinomas treated by radical prostatectomy.
  • Mean patient age at diagnosis was 56 years (range: 44 to 69 y).
  • The mean percentage of tumor composed of the mucinous component was 52% (range: 25% to 90%).
  • Margins were positive in 4 cases of mucinous adenocarcinoma of the prostate.
  • Only 2 cases had isolated margin positivity in the nonmucinous acinar component of cancer.
  • In 12 cases (25.5%), mucinous adenocarcinoma had established extraprostatic extension (EEPE).
  • All together, taking into account both the mucinous and nonmucinous tumor, 20/47 cases (42.5%) had EEPE and 6/47 (12.7%) had positive margins.
  • This study confirms that mucinous adenocarcinoma of the prostate treated by radical prostatectomy is not more aggressive, and possibly even less aggressive than nonmucinous prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Prostatectomy. Prostatic Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300802.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


96. Chang SC, Liao JW, Lin YC, Liu CI, Wong ML: Pancreatic acinar cell carcinoma with intracranial metastasis in a dog. J Vet Med Sci; 2007 Jan;69(1):91-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic acinar cell carcinoma with intracranial metastasis in a dog.
  • This report concerns a case of pancreatic carcinoma with widespread metastases to many organs including intracranial metastasis.
  • An eleven-year-old, male, mixed-breed dog showed emaciation, ataxia, and multiple visible tumors within the neck.
  • Based on gross and microscopic examination, the primary tumor cells were located in the left lobe of the pancreas and widespread metastasis was found into various organs, including the brain, lungs, liver, kidneys, tonsils, serosal surface of the esophagus, and submandibular, pulmonary hilar, mediastinal, and mesenteric lymph nodes.
  • This case indicates that pancreatic adenocarcinoma should be included in the differential diagnosis list when cervical neck masses are detected.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283409.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Stelow EB, Bardales RH, Stanley MW: Pitfalls in endoscopic ultrasound-guided fine-needle aspiration and how to avoid them. Adv Anat Pathol; 2005 Mar;12(2):62-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss the diagnosis of pancreatic ductal adenocarcinoma and of other pancreatic epithelioid tumors including pancreatic endocrine neoplasms, solid pseudopapillary tumors, and acinar cell carcinomas.
  • We also discuss the diagnosis of pancreatic cystic neoplasia including intraductal papillary mucinous neoplasms and mucinous cystic neoplasms and the diagnosis of gastrointestinal mesenchymal neoplasia with particular attention to gastrointestinal stromal tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Fine-Needle / methods. Diagnostic Errors / prevention & control. Endosonography. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731574.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 137
  •  go-up   go-down


98. Uzaslan E, Stuempel T, Ebsen M, Freudenberg N, Nakamura S, Costabel U, Guzman J: Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern. Respiration; 2005 May-Jun;72(3):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern.
  • BACKGROUND: Immunohistochemical studies in human lung carcinoma reported positive staining of tumor cells for surfactant protein A (SP-A), especially in peripheral airway cell carcinoma, which include bronchioloalveolar carcinoma and in some reports also papillary subtypes.
  • OBJECTIVE: The purpose of this study was to determine the SP-A expression in tumor cells of lung adenocarcinoma without a bronchioloalveolar pattern, classified according to the WHO.
  • METHODS: In total, 169 primary adenocarcinomas of the lung (109 acinar, 32 solid with mucin, 24 papillary and 4 mucinous) were examined by immunohistochemistry for SP-A expression.
  • RESULTS: Twenty-five percent of acinar, 38% of papillary and 3% of solid adenocarcinoma with mucin showed a positive intracytoplasmic SP-A reaction of the tumor cells.
  • None of the mucinous adenocarcinomas stained for SP-A.
  • This study included the largest number of acinar adenocarcinomas and solid adenocarcinomas with mucin studied for SP-A.
  • We clearly demonstrated that also primary lung adenocarcinoma without a bronchioloalveolar pattern can express SP-A.
  • A positive staining of hyperplastic type II cells surrounding the tumors or entrapped in the tumor could clearly be differentiated from the SP-A-positive stain of tumor cells.
  • CONCLUSION: These results support the theory that SP-A-producing cells may generate not only bronchioloalveolar and papillary carcinoma, but also other subtypes of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Lung Neoplasms / metabolism. Pulmonary Surfactant-Associated Protein A / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 15942293.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pulmonary Surfactant-Associated Protein A
  •  go-up   go-down


99. Ueda S, Fukamachi K, Matsuoka Y, Takasuka N, Takeshita F, Naito A, Iigo M, Alexander DB, Moore MA, Saito I, Ochiya T, Tsuda H: Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. Carcinogenesis; 2006 Dec;27(12):2497-510
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
  • Pancreatic ductal adenocarcinoma is one of the most debilitating malignancies in humans.
  • One feature of human pancreatic adenocarcinoma is an exceedingly high frequency of K-ras mutation.
  • The present study was conducted to determine if targeted activation of a human oncogenic-ras transgene in rat pancreas would induce carcinomas correspondent to human pancreatic ductal adenocarcinomas.
  • Adenoviral infection of injected animals was exclusive to the pancreas; infected cells could be identified in duct, intercalated duct, centroacinar and, less frequently, acinar cells, but not in endocrine islet cells.
  • Four weeks after injection, proliferative lesions in the duct epithelium, intercalated ducts and centroacinar cells, but not acinar cells, were widespread.
  • Most lesions, including atypical duct proliferative lesions, PanIN-like lesions and carcinomas, were positive for cytokeratins 19 and 7, cyclooxygenase 2 and MMP-7 but negative for amylase and chymotrypsin.
  • Many adenocarcinoma lesions were positive for EGF and EGFR.
  • Duct epithelial and atypical duct proliferative lesions and carcinoma lesions were all positive for transduced Ha-rasG12V oncogene expression.
  • The cytogenesis of pancreatic ductal type carcinoma was depicted.
  • This model exhibits important similarities to the human disease and promises to advance our understanding of the behavior of pancreas adenocarcinomas and expedite screening and therapy.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Genes, ras. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. DNA Primers. Disease Models, Animal. Humans. Mutation. Rats


100. Carvalho S, Branco R, Serralheiro P, Saraiva T, Carvalho L: [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University]. Rev Port Pneumol; 2006 May-Jun;12(3):255-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University].
  • [Transliterated title] Adenocarcinoma do pulmão: Aplicação da classificação WHO 1999/2004 à casuística do Serviço de Anatomia Patológica do Hospital da Universidade de Coimbra.
  • A study of 701 primary adenocarcinomas of the lung was made at the Department of Pathology of the Hospital da Universidade de Coimbra for a period of fifteen years, between 1990 and 2004.
  • The incidence of primary adenocarcinomas varied from 16 cases in 1990 to 49 cases in men and from 12 to 37 cases in women in that period.
  • In the last four years, since 2001, patients were in the seventies at the time of diagnosis and a considerable number of cases were diagnosed after 80 years of age.
  • The criteria defined by the WHO classification of Tumours of the Lung, Pleura, Thymus and Heart 2004 were applied to the primary adenocarcinomas of the lung and as was expected, bronchioloalveolar carcinomas had its incidence in women while acinar adenocarcinomas were diagnosed mainly in men.
  • A number of 109 cases had the final diagnosis of adenocarcinoma of the lung based on morphology and immunohistochemistry criteria.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. International Classification of Diseases. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967175.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down